

1 **Contrasting roles of cytochrome P450s in amitraz and chlorfenapyr resistance in the crop**
2 **pest *Tetranychus urticae***

3 Marilou Vandenhole^{1§}, Xueping Lu^{1§}, Dimitra Tsakireli^{2,3§}, Catherine Mermans¹, Sander De Rouck¹,
4 Berdien De Beer¹, Eba Simma⁴, Spiros A. Pergantis⁵, Wim Jonckheere¹, John Vontas^{2,3}, Thomas Van
5 Leeuwen^{1*}

6 ¹Department of Plants and Crops, Faculty of Bioscience Engineering, Ghent University, Coupure links 653, Ghent, Belgium.

7 ² Laboratory of Pesticide Science, Department of Crop Science, Agricultural University of Athens, 75 Iera Odos Street, GR-
8 11855 Athens, Greece

9 ³ Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology Hellas, GR-700 13 Heraklion,
10 Crete, Greece

11 ⁴Department of Biology, College of Natural Sciences, Jimma University, Jimma, Ethiopia.

12 ⁵ Environmental Chemical Processes Laboratory, Department of Chemistry, University of Crete, Voutes Campus, 70013,
13 Heraklion, Crete, Greece

14

15 [§]These authors contributed equally

16 *Corresponding author: thomas.vanleeuwen@ugent.be

17

18

19

20 **Key words:** gene regulation, acaricide resistance, detoxification, genetic mapping,
21 mitochondrial uncouplers, octopamine receptor, spider mite

22

23 **Abstract**

24 The molecular mechanisms of amitraz and chlorfenapyr resistance remain only poorly
25 understood for major agricultural pests and vectors of human diseases. This study focusses on
26 a multi-resistant field strain of the crop pest *Tetranychus urticae*, which could be readily
27 selected in the laboratory to high levels of amitraz and chlorfenapyr resistance. Toxicity
28 experiments using tralopyril, the active toxophore of chlorfenapyr, suggested decreased
29 activation as a likely mechanism underlying resistance. Starting from the same parental strain,
30 transcriptome profiling revealed that a cluster of detoxifying genes was upregulated after
31 amitraz selection, but unexpectedly downregulated after chlorfenapyr selection. Further
32 functional validation associated the upregulation of CYP392A16 with amitraz metabolism and
33 the downregulation of CYP392D8 with reduced activation of chlorfenapyr to tralopyril. Genetic
34 mapping (QTL analysis by BSA) was conducted in an attempt to unravel the genetic
35 mechanisms of expression variation and resistance. This revealed that chlorfenapyr resistance
36 was associated with a single QTL, while 3 QTLs were uncovered for amitraz resistance.
37 Together with the observed contrasting gene expression patterns, we argue that transcriptional
38 regulators most likely underly the distinct expression profiles associated with resistance, but
39 these await further functional validation.

40

41 **1 Introduction**

42 The two-spotted spider mite, *Tetranychus urticae* Koch (Acari: Tetranychidae), is a
43 cosmopolitan agricultural pest known for its exceptionally wide host range (Grbić et al., 2011).
44 This pest can feed on over 1100 plant species from more than 140 different families, including
45 some well-known toxin-producing plants (Migeon et al., 2010). With the potential to severely
46 infest more than 150 annual and perennial crops and ornamental plant species, *T. urticae* poses
47 a significant economic threat in greenhouses and field crops (Grbić et al., 2011; Van Leeuwen
48 et al., 2010). Synthetic acaricides play a crucial role in the management of *T. urticae* in many
49 agronomic crops due to their effectiveness, ease of use, and low cost (Damalas, 2009; Van
50 Leeuwen et al., 2015). Unfortunately, *T. urticae* is notorious for its ability to quickly develop
51 resistance to a variety of acaricides due to its high fecundity, rapid development and
52 arrhenotokous reproduction (De Rouck et al., 2023; Van Leeuwen and Dermauw, 2016).
53 According to the Arthropod Pesticide Resistance Database
54 (<http://www.pesticideresistance.org>), there have been 432 recorded cases of resistance to 96
55 active ingredients for *T. urticae*, including major groups of currently used acaricides (David
56 and John, 2023; De Rouck et al., 2023; Riga et al., 2017; Sparks and Nauen, 2015; Van Leeuwen
57 and Dermauw, 2016). The rising cost of discovery, development, and registration have made
58 the agro-industry more reluctant to develop new crop protection chemicals (Sparks, 2013).
59 Therefore, there is a pressing need for improved evidence-based integrated resistance
60 managements (IRM), including appropriate application of existing acaricides. One alternative
61 approach to the current use-and-dispose method might be to employ negative cross-resistance
62 (NCR) strategies to manage organisms that already show resistance against various compounds.
63 NCR describes a phenotype in which a strain has developed resistance to one pesticide but
64 shows greater sensitivity to some pesticides. Recent studies and reviews have emphasized the
65 potential of use of pro-pesticides for resistance management, as they show most cases of NCR
66 (David, 2021). Amongst these pro-pesticides, chlorfenapyr is particularly noteworthy as there
67 are numerous cases of NCR across arthropods (David, 2021; Leonard, 2000; Nicastro et al.,
68 2013).

69 Chlorfenapyr is a broad-spectrum pyrrole pesticide belonging to IRAC Group 13 and is mainly
70 used for termite control and crop protection against a variety of insect and mite pests (Lovell et
71 al., 1990; Pimprale et al., 1997; Sheppard and Joyce, 1998; Sparks and Nauen, 2015).
72 Chlorfenapyr is a pro-acaricide which needs oxidative removal of the N-ethoxymethyl group *in*
73 *vivo* to activate its pesticidal potential and form the toxic metabolite tralopyril. Tralopyril is a

74 lipophilic compound with weakly acidic properties due to the presence of an acidic proton in
75 the pyrrole ring and thus exhibits protonophoric activities. It acts by transporting protons across
76 the mitochondrial membrane, thereby interfering with mitochondrial oxidative phosphorylation.
77 This disruption of ATP synthesis leads to cell dysfunction and ultimately the demise of the
78 target organism (Black et al., 1994; Raghavendra et al., 2011b; Terada, 1990). Another
79 important but less studied pro-acaricide is amitraz. Amitraz is a formamidine pro-pesticide
80 belonging to IRAC Group 19 (Hollingworth, 1976; Sparks et al., 2021). Amitraz can act as an
81 agonist by stimulating the β -adrenergic-like octopamine receptors (β AOR), but its active
82 metabolite, DPMF (N^2 -(2,4-dimethylphenyl)- N^1 -methylformamidine), is an even stronger
83 agonist (Cai et al., 2023; Kita et al., 2017; Takata et al., 2020). Important to note is the observed
84 strong connection from toxicity bioassays between chlorfenapyr and amitraz resistance in *T.*
85 *urticae* strains (Aguilar-Medel et al., 2011; Al-Antary et al., 2012; Herron and Rophail, 2003;
86 Simma et al., 2020; Van Leeuwen et al., 2005, 2004). This observation raises the question of
87 whether a “hitchhiking effect” is at play, wherein two closely linked pesticide resistance genes
88 under one acaricide pressure are simultaneously favored (Kojima and Schaffer, 1967; Smith
89 and Haigh, 1974), or if a single evolved gene provides resistance to more than one molecule
90 (Duarte et al., 2022). The level of connection between chlorfenapyr and amitraz – two
91 compounds with completely different MOAs, targeting respiration and neural functions
92 respectively – could heighten concerns for pest resistance management. Therefore,
93 understanding the mechanisms behind resistance and cross-resistance would help making
94 informed decisions regarding the optimal use and rotation of pesticides, thereby delaying the
95 evolution of resistance and prolonging their efficacy (Dekeyser, 2005). This might be especially
96 important for chlorfenapyr, that is currently also implemented in mosquito control programs as
97 one of the few alternatives (Ngufor et al., 2016; Tchouakui et al., 2023).

98 Resistance can evolve via two main mechanisms: alterations in the coding sequence of acaricide
99 target genes due to various point mutations leading to decreased acaricide sensitivity
100 (toxicodynamic resistance), or changes in factors affecting absorption, excretion, distribution
101 and metabolism, impacting the overall effectiveness of the acaricide (toxicokinetic resistance)
102 (De Rouck et al., 2023; Feyereisen et al., 2015). Interestingly, a recent study has shown that
103 resistance against pro-insecticides was mediated by downregulation of detoxification enzymes
104 involved in the activation (Vlogiannitis et al., 2021). Although only relatively few studies have
105 investigated chlorfenapyr resistance mechanisms in spider mites, multiple potential
106 mechanisms have been described based on synergist and/or total enzyme assays. These include

107 metabolic detoxification mediated by carboxyl/cholinesterases, glutathione S-transferases
108 (GSTs) and cytochrome P450s (P450s), as well as decreased cuticular penetration (Li et al.,
109 2005; Van Leeuwen et al., 2006, 2004). Moreover, the induction of P450 activity by barbital
110 and geraniol has been shown to increase chlorfenapyr tolerance in *T. urticae*, possibly through
111 increased detoxification (Van Pottelberge et al., 2008). However, those mechanisms can only
112 explain a part of the resistant phenotype, and the precise underlying mechanisms remain largely
113 unknown. In any case, it is likely that metabolic resistance mechanisms are at play because
114 uncouplers like chlorfenapyr do not bind to a specific protein (target-site), unlike most
115 insecticides and acaricides. Also for amitraz, the resistance mechanisms in spider mites have
116 remained largely elusive. However, studies on other tick and mite species suggested the
117 involvement of target-site mutations in the octopamine/tyramine (OCT/Tyr) receptors, the β -
118 adrenergic octopamine receptor (β OAR) or its 5' untranslated region (UTR) (Baron et al., 2015;
119 Corley et al., 2013; De Rouck et al., 2023). However, synergist experiments also suggest the
120 involvement of P450s (Chevillon et al., 2007; Ducornez et al., 2005). Nevertheless, amitraz
121 resistance mechanism are despite their importance only poorly studied in mites and ticks. Spider
122 mites like *T. urticae*, with a wealth of available toxicological and genetic tools (De Rouck et al.
123 2023), might be useful to resolve some of the standing questions in the field for both amitraz
124 and chlorfenapyr (cross-)resistance mechanisms.

125 A previous screening study identified an Ethiopian field strain of *T. urticae* resistant to both
126 chlorfenapyr and amitraz (Simma et al., 2020). Here, we took advantage of this strain to study
127 the molecular mechanisms of resistance. For this purpose, this strain was further selected in the
128 laboratory with chlorfenapyr and amitraz separately and the phenotypic strength of resistance
129 was quantified. Considering reduced activation as a potential resistance mechanism in
130 chlorfenapyr resistance, also toxicity of the active metabolite tralopyril was assessed. Next,
131 synergist assays were conducted to explore the potential involvement of detoxification enzymes
132 in resistance mechanisms against both acaricides, followed by transcriptome sequencing of
133 parental and selected populations with and without acaricide exposure. Identified candidate
134 P450s were validated *in vitro* via recombinant expression and metabolic assays. We further
135 tried to unravel the genetic complexity of chlorfenapyr/amitraz resistance by genetic mapping
136 via bulked segregant analysis (BSA).

137 **2. Materials and methods**

138 2.1 Chemicals used

139 The acaricides used for strain selection and toxicity bioassays were a commercial formulation
140 of amitraz (Mitac; 20 g a.i. L⁻¹ EC) from Arysta Life Science (Ethiopia) and chlorfenapyr (240
141 g a.i. L⁻¹ SC) from BASF (Canada) for experimental use. The analytical standard of tralopyril
142 (CAS 122454-29-9) was purchased from LGC (UK). Technical grade amitraz and chlorfenapyr
143 were purchased from Sigma Aldrich (USA). The synergists diethyl maleate (DEM) and
144 piperonyl butoxide (PBO) were of analytical grade and purchased from Sigma-Aldrich
145 (Belgium), S,S,S-tributyl phosphorotrithioate (DEF) was purchased from Chemservice (USA).

146 2.2 Spider mite strains

147 Two *T. urticae* strains originally collected from Ethiopia were used: Jimma Wild and Holeta-2.
148 Jimma Wild (abbreviation JW) was collected in 2018 from wild ornamentals in Jimma, while
149 the Holeta-2 parental strain (abbreviation HP) was collected from greenhouse strawberry plants
150 in Holeta in 2019 (Simma et al., 2020). HP was highly resistant to fenbutatin oxide, amitraz and
151 fenpyroximate, but also moderately resistant to chlorfenapyr (Simma et al., 2020). The HP
152 strain was used to set-up laboratory-selection with both chlorfenapyr and amitraz, giving rise
153 to the resistant strains HPC and HPA, respectively. The strains were maintained on sprayed
154 kidney bean plants (*Phaseolus vulgaris* var. Prelude) at a constant selection pressure of 500 mg
155 L⁻¹ chlorfenapyr and 1000 mg L⁻¹ amitraz. JW, which was susceptible to both chlorfenapyr and
156 amitraz (Simma et al., 2020), was reared on untreated kidney bean plants. Additionally, two
157 laboratory strains were used: the susceptible reference strain London (abbreviation LON)
158 (Grbić et al., 2011), and the inbred strain ROS-ITi which originated from the ROS-IT strain
159 after 7-8 generations of consecutive mother-son mating (De Beer et al., 2022a; Kurlovs et al.,
160 2022). ROS-ITi was highly susceptible to most tested acaricidal compounds, with the exception
161 of dicofol (Kurlovs et al., 2022). Both LON and ROS-ITi were maintained on untreated bean
162 plants. All strains were kept in climatically controlled rooms at 25 ± 1 °C, 60% relative humidity
163 (RH), 16:8 h light:dark photoperiod. Fresh potted bean plants were offered when needed.

164 2.3 Toxicity bioassays

165 Full dose-response adulticidal toxicity bioassays were performed as described previously
166 (Khajehali et al., 2011). Briefly, 20-30 adult female mites were transferred to the upper side of
167 9 cm² square bean leaf discs placed on wet cotton wool. The acaricides amitraz and chlorfenapyr
168 were diluted with water and the technical standard tralopyril was formulated in a mixture of
169 N,N-dimethylformamide (DMF) and alkyl-aryl polyglycol ether (emulsifier W) (3:1 w:w), and

170 subsequently 100-fold diluted with water to form a stock solution. To determine the lethal
171 concentration 50 (LC₅₀), a minimum of five concentrations was tested in four replicates, along
172 with blank controls that were sprayed with deionized water or a blank formulation (1/100
173 dilution of mix of DMF and emulsifier W) for tralopyril bioassays. Mites were sprayed with
174 0.8 ml of serial acaricide dilutions at 1 bar pressure using a Cornelis spray tower resulting in a
175 homogenous spray film of 2.00 ± 0.05 mg cm⁻² aqueous acaricide deposit (Van Laecke and
176 Degheele, 1993). Mortality was scored after 72 h and mites were scored as “dead” if they did
177 not move one body length within 10 seconds after being prodded with a fine brush. Dose-
178 response relationships (LC₅₀ and 95% confidence interval (CI)) were calculated from probit
179 regression using PoloPlus software (LeOra software, USA).

180 **2.4 Determining the mode of inheritance of chlorfenapyr resistance**

181 To estimate the degree of dominance and to identify potential maternal inheritance of
182 chlorfenapyr resistance, mites of the susceptible LON and chlorfenapyr resistant HPC strain
183 were reciprocally crossed to produce hybrid F₁ females, as previously described (Van
184 Pottelberge et al., 2009), and used for toxicity bioassays as described above. Dominance was
185 determined using the Stone formula (Stone, 1968); dominance (D) is given by $D = \frac{2X_2 - X_1 - X_3}{X_1 - X_3}$,
186 where $X_1 = \log LC_{50}$ of the resistant strain (HPC), $X_2 = \log LC_{50}$ of the F₁ females (HPC ♀ ×
187 LON ♂ or LON ♀ × HPC ♂) and $X_3 = \log LC_{50}$ of the susceptible strain (LON). The number
188 of genes associated with chlorfenapyr resistance was estimated via an F₂ backcrossing
189 experiment. F₁ heterozygous unfertilized females from the reciprocal cross (LON ♀ × HPC ♂)
190 were allowed to mate with susceptible LON males on bean leaves for two days. The resulting
191 1-3 days old F₂ females were then subjected to toxicity bioassays as described above. Single
192 gene inheritance is characterized by a plateau at 50% mortality of the concentration-mortality
193 curves. The expected responses of monogenic F₂ females for each given dose were calculated
194 using the following formula of Georghiou (1969): $c = (0.5) W_{LON \times HPC} + (0.5) W_{LON}$, where c is
195 the expected mortality at each given concentration and W is the observed mortality of the F₁
196 LON × HPC and parental LON genotypes at each given concentration. The dose-response
197 curves (Abbott corrected mortality (Abbott, 1987)) were plotted using Sigmaplot (v.14.5)
198 (Systat, USA). The χ^2 goodness-of-fit test was applied to determine how well the observed
199 responses matched the expected.

200 **2.5 Synergism/antagonism experiments**

201 In order to investigate the potential involvement of metabolic resistance mechanisms, synergist
202 bioassays were performed as described earlier (Snoeck et al., 2017; Van Pottelberge et al., 2009).
203 About 30 young adult female mites were placed on bean leaf discs and sprayed with a non-toxic
204 concentration of 1000 mg L⁻¹ PBO, 2000 mg L⁻¹ DEM or DEF, dissolved in a mixture (3:1 w:w)
205 of DMF and emulsifier W and subsequently 100-fold diluted with deionized water. Final
206 concentrations for DEF were 300 mg L⁻¹ for JW and 500 mg L⁻¹ for HPC and HPA, in order to
207 keep mortality below 5-10%. Mites were sprayed with diluted formulations with or without
208 (control) synergists, and subsequently placed in a climatically controlled room as described
209 above. After 24 h, surviving mites were transferred to fresh leaf discs and used in toxicity
210 bioassays with chlorfenapyr or amitraz. Mites sprayed with water served as the control. LC₅₀'s
211 and their 95% CI were determined with PoloPlus software. Synergism ratios (SRs) were
212 calculated by dividing the LC₅₀ values from experiments with synergists by LC₅₀ values from
213 experiments without synergists.

214 **2.6 Transcriptome analysis**

215 *2.6.1 RNA extraction and sequencing*

216 Prior to RNA extraction, both the amitraz- (HPA) and chlorfenapyr-resistant (HPC) strains were
217 placed on unsprayed plants for one generation (\pm 7 days) ,except for HPAexp and HPCexp
218 strains which experienced continuous exposure. Total RNA was extracted from a pool of 100-
219 120 adult female mites using the Rneasy Mini Kit (Qiagen, Belgium). Four replicates were
220 included for each population: LON, JW, HP, HPA, HPC, HPAexp, and HPCexp. The quality
221 and quantity of the total RNA was analyzed using a DeNovix DS-11 spectrophotometer
222 (DeNovix, USA) and by running an aliquot on a 1% agarose gel. RNA samples were
223 subsequently sent to Macrogen (The Netherlands) for mRNA library construction and
224 sequencing. Libraries were constructed with TruSeq Stranded mRNA Library Preparation Kit
225 (Illumina, USA) and sequenced via Illumina's NovaSeq6000 platform to generate stranded,
226 paired-end reads of 100 bp.

227 *2.6.2 RNA read mapping and PCA*

228 The quality of the RNA reads was assessed using the FastQC software (v.0.11.9) (Andrews,
229 2010). RNA reads were aligned to the three pseudochromosome assembly of *T. urticae* using
230 the two-pass alignment mode of STAR (v.2.7.9a) with a maximum intron size set to 20 kb
231 (Dobin et al., 2013; Wybouw et al., 2019). After alignment, the BAM files were sorted by

232 chromosomal coordinate and indexed using SAMtools (v.1.15) (Li et al., 2009). The resulting
233 coordinate-sorted BAM files were used as an input for HTSeq (v.0.11.2) for read-counting on
234 a per-gene basis with the flags “*-stranded yes*” and “*-feature exon*” (Anders et al., 2015). A
235 principal component analysis (PCA) was done based on the resulting read-count files using the
236 R-package DESeq2 (v.1.34.0) in order to investigate transcriptional differences within and
237 between treatment groups (LON, JW, HP, HPA, HPAexp, HPC and HPCexp) (Love et al.,
238 2014). In short, the regularized-logarithm (rlog) transformation function of the DESeq2
239 package was used to normalize the counts and PlotPCA to calculate and plot the PCA for the
240 5000 most variable genes across all samples.

241 2.6.3 K-means clustering analysis

242 All genes showing differential expression across at least one of the different conditions were
243 clustered using the k-means clustering algorithm. In order to do this, first DESeq2 analysis was
244 performed with a Likelihood Ratio Test (LTR) on the reduced model to analyze all levels of a
245 factor at once. Only genes that had an adjusted p value (p adj) < 0.001 were filtered out as genes
246 that show significant differences in expression in at least one of the conditions. The normalized
247 read-counts of these genes were transformed into a z-scaled distance dataset using the Pearson
248 method with the “*get_dist*” function within the R-package factextra (v.1.0.7). This z-scaled
249 dataset was subsequently used as an input for the k-means clustering algorithm using the
250 “*kmeans*” function of the R-package stats (v.4.3.1). The optimal number of 13 clusters was
251 determined using the gap statistic (maximum of number of 25, first max, seed set at 123, nstart
252 set at 25 and the maximum number of iterations set at 50) (Tibshirani et al., 2001). The z-scaled
253 dataset of all genes showing significant differential expression amongst the samples was used
254 to make a heatmap with the R-package pheatmap (v.1.0.12), where rows represent the genes
255 that are grouped according to their respective clusters. For each cluster, plots were made
256 representing the average z-score per treatment group per gene in the cluster, which was
257 thereafter used to calculate the average z-score trend with standard deviation across all genes
258 in the cluster.

259 The R function enricher from the package clusterProfiler (v.4.2.2) was used for GO enrichment
260 analysis of each cluster of genes. The GO terms for “Biological Processes”(BP) and “Molecular
261 Functions” (MF) were collected based on the *T. urticae* annotation (v.20190125) from the
262 ORCAE database (Sterck et al., 2012). The argument “*pAdjustMethod = 'BH'*” was added to
263 the function in order to perform multiple correction using a Benjamini-Hochberg procedure.

264 2.6.4 Pairwise differential expression analysis

265 DESeq2 (v.1.34.0) was used to perform a pairwise differential expression analysis between all
266 strains (LON, JW, HP, HPA, HPC, HPAexp and HPCexp) based on the total read-counts per
267 gene generated by HTSeq (as described in section 2.6.2). Differentially expressed genes (DEGs)
268 were classified as genes with an absolute Log₂ Fold Change ($|\text{Log}_2\text{FC}| > 1$) and a Benjamini-
269 Hochberg adjusted p value ($p \text{ adj} < 0.05$) in the pairwise comparison. A gene expression
270 heatmap for all full-length P450 genes (list published by Kurlovs et al., 2022) was generated
271 using the relative transcript levels (Log_2FC) of the four differential expression comparisons
272 between HP and the derived selected strains (HPA vs HP, HPAexp vs HP, HPC vs HP and
273 HPCexp vs HP) using the pheatmap function in R. P450s were clustered using the Euclidian
274 distance, and P450s that were not differentially expressed ($|\text{Log}_2\text{FC}| < 1$ and/or $p \text{ adj} > 0.05$) in
275 all four comparisons were excluded from the heatmap.

276 2.7 P450 functional expression and metabolism assay

277 Metabolism assays of P450s with amitraz and chlorfenapyr were performed to investigate their
278 potential role in amitraz/chlorfenapyr resistance or selectivity. The P450 genes *CYP392A16*,
279 *CYP392A11*, *CYP392E10*, *CYP392D8* and *CYP392A1*, which each showed an interesting
280 expression pattern in transcriptomic analysis, were selected to be functionally expressed *in vitro*
281 as described previously (Riga et al., 2014).

282 2.7.1 P450 HPLC-UV activity assay

283 Stock concentrations of amitraz (100 % purity, Sigma Aldrich, USA) and DPMF (100% purity,
284 Sigma Aldrich, USA) were prepared and diluted in acetonitrile. Stock concentrations of
285 chlorfenapyr (100 % purity, Sigma Aldrich, USA) were prepared and diluted in methanol.
286 Standard reactions contained a final organic solvent concentration between 2-2.5% (v/v) with
287 25 μM amitraz, 25 μM DPMF or 20 μM chlorfenapyr, respectively, and 5-25 pmol bacterial
288 membranes from each of the P450s in 100 μl Tris-HCl buffer (0.2 M, pH 7.4), containing 0.25
289 mM MgCl_2 . The incubation was performed in the presence and absence of an NADPH
290 generating system: 1 mM glucose-6-phosphate (Sigma Aldrich, USA) 0.1 mM NADP^+ (Sigma
291 Aldrich, USA) and 1 unit/ml glucose-6-phosphate dehydrogenase (G6PDH-, Sigma Aldrich,
292 USA). The reactions were incubated at 30 °C with 1250 rpm oscillation and stopped at 0, 15
293 min, and 2 h time points using 100 μl acetonitrile and stirred additionally for 30 min. Finally,
294 the quenched reactions were centrifuged at 10,000 rpm for 10 min and the supernatant was
295 transferred to HPLC vials, with 100 μl of the supernatant loaded for HPLC analysis. Reactions

296 were performed in triplicate and compared against a negative control with no NADPH
297 regenerating system to calculate substrate depletion. Amitraz, DPMF and chlorfenapyr were
298 separated on a 5 μm C18 (250 mm \times 4.5 mm) reverse phase analytical column (Fortis
299 Technologies, UK). Amitraz was separated using an isocratic mobile phase of 80% acetonitrile
300 and 20% H_2O with a flow rate of 1.5 ml min^{-1} for 20 min. Reactions were monitored by changes
301 in absorbance at 313 nm and quantified by peak integration (Chromeleon, Dionex). For enzyme
302 reaction kinetics, different concentrations of amitraz were used. Rates of substrate turnover
303 from two independent reactions were plotted versus substrate concentration. K_m , V_{max} and
304 K_{cat} were determined using SigmaPlot (v.12.0) (Systat Software, UK). DPMF was separated
305 under binary gradient conditions. The program used was initially 1.5 min with an isocratic
306 mobile phase of acetonitrile, 0.01 M TEA, pH 6.1 (adjusted with 0.75 M H_3PO_4), 30:70 (v/v),
307 and then a linear gradient was applied arriving at 100% acetonitrile at 20 min. The flow rate
308 was 1 mL/min. Reactions were monitored by changes in absorbance at 210 nm and quantified
309 by peak integration (Chromeleon, Dionex). Chlorfenapyr was separated on a 5 μm C18 (250
310 mm \times 4.5 mm) reverse phase analytical column (Fortis Technologies, UK). Reactions with
311 chlorfenapyr were separated using an isocratic mobile phase of 85% methanol and 15% of 40
312 mM ammonium acetate in water with a flow rate was 0.8 ml min^{-1} for 7 min.

313 2.7.2 Identification of reaction products of amitraz and chlorfenapyr by LC-MS analysis

314 The reactions of the P450 enzymes with amitraz and chlorfenapyr, respectively, in the presence
315 and absence of an NADPH generating system were further analyzed using a high-resolution
316 HPLC-MS/MS system. Sample injections of 1 μl and 10 μl volumes were performed for amitraz
317 and chlorfenapyr, respectively, via an Ultimate 3000 Autosampler (Thermo Scientific, USA).
318 Chromatographic separation was achieved using an Ultimate 3000 (Thermo Scientific, USA),
319 equipped with a 3 μm C18 (100 x 2.1 mm) reverse phase analytical column (Fortis Technologies,
320 UK). Amitraz reactions were analyzed with an isocratic mobile phase of 85% acetonitrile and
321 15% H_2O with a flow rate of 0.2 ml min^{-1} for 12 min. Chlorfenapyr reactions were analyzed
322 with an isocratic mobile phase of 85% MeOH and 15% of 40 mM ammonium acetate, with a
323 flow rate of 0.2 ml min^{-1} for 7 min. Analyte detection was achieved using an electrospray
324 ionization (ESI) Q Exactive Hybrid Quadrupole-Orbitrap Mass Spectrometer (Thermo
325 Scientific, USA), operated in the positive ion mode for amitraz and in the negative ion mode
326 for chlorfenapyr. Mass spectrometry was operated both in full scan/extracted ion monitoring
327 and parallel reaction monitoring (PRM). The system was controlled by the Xcalibur (v.4.0)
328 software (Thermo Scientific, USA), which was also used for data acquisition and analysis. The

329 optimum mass spectrometer parameters were set as follows: spray voltage at 4000 V for amitraz
330 and 3500 V for chlorfenapyr respectively, sheath gas pressure at 20 arbitrary units, auxiliary
331 gas pressure at 25 arbitrary units, ion transfer capillary temperature at 350 °C. In the parallel
332 reaction monitoring for amitraz, the source collision induced dissociation at 20 eV. Sheat/aux
333 and collision gas were high purity nitrogen. The reference substrate, tralopyril, was analyzed
334 under the same experimental conditions as chlorfenapyr.

335 **2.8 QTL mapping with bulked segregant analysis (BSA)**

336 2.8.1 Experimental evolution setup

337 A mapping population was generated by placing 37 virgin adult females of the susceptible
338 inbred ROS-ITi strain together with a single young male of the resistant HPC strain on a
339 detached bean leaf. The resulting F₁ population was expanded in a climatically controlled
340 chamber for 4-5 generations to generate a large segregating bulk population. From this bulk, 10
341 subpopulations were established via transfer of 500 individuals per subpopulation to potted
342 bean plants placed in a mite-proof cage (BugDorm-4F4590DH, MegaView ScienceCo.,
343 Taiwan). These subpopulations were allowed to grow for around 5 generations under
344 greenhouse conditions (20-25 °C and 50-80% relative humidity). Next, a paired amitraz- and
345 chlorfenapyr-selected population was established from each of these 10 control populations by
346 transferring around 500 adult female mites to new potted bean plants, giving rise to a total of
347 30 experimental populations (10 untreated control + 10 amitraz-treated + 10 chlorfenapyr-
348 treated). Bean plants were sprayed with a gradually increasing concentration of amitraz or
349 chlorfenapyr using a hand-held spraying device (Birchmeier, Switzerland). The initial selection
350 concentration was 50 mg L⁻¹ of amitraz and 10 mg L⁻¹ chlorfenapyr, which over the course of
351 ± 25 generations increased to 1000 mg L⁻¹ amitraz and 500 mg L⁻¹ chlorfenapyr, respectively.
352 Prior to DNA extractions, acaricide susceptibility were evaluated by conducting dose-response
353 bioassays on all amitraz/chlorfenapyr-selected and control subpopulations, following the
354 procedure detailed in Section 2.3. Selected subpopulations were kept on unsprayed plants for
355 one generation (10 days) before the bioassays were conducted. Mortality percentages between
356 the paired selected and control populations were analyzed using a generalized mixed model,
357 with a binomial distribution (SPSS v.28). Selection regime and dosage were incorporated as
358 fixed effects in the linear model, whereas population was regarded as a random effect (Wybouw
359 et al., 2019).

360 2.8.2 DNA extraction, genome sequencing, mapping and variant detection

361 At the end of the selection experiment, after approximately 9 months (\pm 25 generations), 800
362 adult female mites were collected from each of the 30 subpopulations for genomic DNA (gDNA)
363 extraction. gDNA was extracted following the phenol-chloroform-based protocol as described
364 previously (Russell and Sambrook, 2001; Van Leeuwen et al., 2008). Quantity and quality of
365 gDNA was evaluated using a Denovix DS-11 spectrophotometer (DeNovix, USA) and by
366 running 2% agarose gel electrophoresis (30 min at 100 V), respectively. During the initial phase
367 of the QTL mapping experiment, a sample of 800 female mites of the resistant parental strain
368 (HPC) was collected, and genomic DNA was extracted using the method described above. The
369 genomic DNA data of the other susceptible parental inbred strain, ROS-ITi, was obtained from
370 research conducted by Kurlovs et al. (2022). Illumina libraries were constructed using the
371 TruSeq DNA PCR-free sample preparation kit and sequenced using the Illumina Novaseq 6000
372 technology, generating paired-end reads of 150 bp with a mean insert size of 350 bp. Genomic
373 sequence reads for all BSA populations as well as the HPC strain were deposited in the NCBI
374 Sequence Read Archive (SRA) under BioProject (PRJNA1033831), whereas the genomic
375 sequence reads of the ROS-ITi strain were made available by Kurlovs et al. (2022) on the NCBI
376 SRA under BioProject PRJNA799176. The resulting reads were aligned to the three
377 pseudochromosome assembly of the *T. urticae* genome (Wybouw et al., 2019) using the BWA-
378 MEM algorithm (v.0.7.17-r1188) with default settings. Subsequently the alignments were
379 processed and position-sorted using SAMtools (v.1.11) and duplicates were marked using the
380 Picard toolkit (v.2.20.4-SNAPSHOT). Next, HaplotypeCaller was used from the GATK
381 package (v.4.1.7.0) to perform joint variant calling across all 30 subpopulations and the parental
382 strains, which produced a variant call format (VCF) file containing single nucleotide
383 polymorphisms (SNPs) and indels. The GATK tools CombineGVCF and GenotypeGVF were
384 used to combine the gVCF's of each BSA population and the parental strains into one single
385 VCF and do the genotyping, respectively.

386 2.8.3 PCA, BSA and SNPeff

387 To inspect the variability between and within treatment group samples, a principal component
388 analysis (PCA) was performed using the R package prcomp (v.4.2.1), as described by Snoeck
389 et al. (2019). More specifically, this method uses a correlation matrix containing the individual
390 SNP frequencies as an input, and only selects SNP alleles that differentiated the two parental
391 strains from the BSA, and were present in every treatment group (amitraz-selected,
392 chlorfenapyr-selected and control). The PCA is represented as a two-dimensional plot with PC1

393 and PC2, using the function autoplot in the R package ggplot2 (v.3.3.6). The BSA analysis was
394 performed via the script “RUN_BSA1.02.py”, available at <https://github.com/rmclarklab/BSA>,
395 using the final gVCF as input with default settings for paired offspring data with a haplodiploid
396 male parent and the flags “-perm” set to 10000 and “-sig” set to 0.05 (Kurlovs et al., 2019).
397 The final gVCF file was also used as input for the R package Gviz (v.1.40.1) (Hahne and Ivanek,
398 2016) for visualization of genes within interesting regions below the QTL peak, based on the
399 GFF3 annotation of the *T. urticae* three pseudochromosome assembly published by Wybouw
400 et al (2019) (Wybouw et al., 2019).

401 The package SnpEff (v.5.0c) (Cingolani et al., 2012b) was used to mine the variants predicted
402 by GATK in the regions of the three QTLs identified in both BSA assays for SNPs and small
403 indels with ‘HIGH’ and ‘MODERATE’ effects on the coding sequence. To this end, SnpEff
404 uses a database derived from the three pseudochromosome assembly of the *T. urticae* genome
405 (Wybouw et al., 2019) together with the *T. urticae* coding sequence database originating from
406 the annotation of 23 June 2016 (available on the Online Resource for Community Annotation
407 of Eukaryotes—ORCAE) (Sterck et al., 2012). Next, the tool SnpSift (Cingolani et al., 2012a)
408 within the SnpEff package was used to filter the SnpEff output in the region of the common
409 upward facing peak of QTL 1 for variants present in the resistant parent (HPC), absent in the
410 susceptible parent (ROS-ITi) and enriched in all amitraz- or chlorfenapyr-selected populations
411 (i.e., the allelic depth of the variant allele being higher than the allelic depth of the reference
412 allele). For the BSA selected with amitraz, two additional downward facing peaks (QTL2 and
413 QTL3) were identified for which the SnpEff output was filtered with SnpSift for variants where
414 the reference allele was enriched in all amitraz-selected populations as compared to the control
415 populations (i.e., the allelic depth of the variant allele being lower than the allelic depth of the
416 reference allele). The variants predicted by GATK were also mined for SNPs and small indels
417 with ‘HIGH’ and ‘MODERATE’ effects on the coding sequence of the hypothesized target-site
418 genes of amitraz; the beta-adrenergic octopamine receptor (βOAR , *tetur08g04980*) and the
419 octopamine-tyramine receptor (*tetur25g01530*).

420 Differential expression of the genes within the peak regions between the parents ROS-ITi and
421 HPC was studied using the methods explained in Section 2.6. Transcriptomic data of ROS-ITi
422 was made publicly available by Kurlovs et al. (2022) on the NCBI SRA database under
423 BioProject PRJNA801103.

424 2.9 RNAi experiment

425 In order to test the hypothesis that the cluster of HR96-LBD genes located at QTL1 are the
426 transcriptional regulators driving the contrasting resistance phenotypes, an RNAi experiment
427 knocking down this cluster of genes was conducted. Gene-specific primers that contain 20 bases
428 of the T7 promoter were designed using E-RNAi and si-Fi (Horn and Boutros, 2010; Lück et
429 al., 2019) to amplify (1) *tetur03g00690*, *tetur03g00710*, *tetur03g00730* and *tetur03g00740*
430 from cDNA of strain HPA and (2) GFP from plasmid DNA (primer info listed in
431 **Supplementary Table 1**). Using the Maxima First Strand cDNA synthesis kit (Thermo Fisher
432 Scientific, USA) cDNA from HPA was obtained via reverse transcription of RNA.
433 Amplification was performed by PCR using GoTaq G2 Flexi DNA polymerase (Promega, USA)
434 with initial denaturation at 95 °C for 2 min, followed by 35 cycles of amplification (95 °C for
435 30 s, 53 °C for 30s, 72 °C for 1 min) and a final extension at 72 °C for 5 min. PCR products
436 were purified using E.Z.N.A. Cycle Pure kit (Omega Bio-Tek, USA) of which quality and
437 quantity was verified using a DeNovix DS-11 FX spectrophotometer (DeNovix, USA) and by
438 running an aliquot on a 2% agarose gel. Next, 1 µg of the T7 PCR template was used for dsRNA
439 synthesis using the TranscriptAid T7 High Yield Transcription kit (Thermo Fisher Scientific,
440 USA) according to the manufacturer's instructions with a reaction volume of 20 µl and an
441 incubation at 37°C overnight. After synthesis, T7 PCR template was degraded by DNase I
442 treatment and dsRNA was purified by chloroform-phenol extraction. Concentrations were
443 evaluated using a DeNovix® DS-11 FX spectrophotometer (DeNovix, USA) and integrity was
444 verified by 2% agarose gel electrophoresis. Injections of dsRNA were performed as described
445 by Dermauw et al. (Dermauw et al., 2020a). Briefly, 120 2-3 days old adult female mites of the
446 HPA strain were immobilized and injected with a mix of all four dsRNA fragments (500 ng/µl
447 each) under a Leica S8 APO microscope (Leica Microsystems, Germany) with a Nanoject III
448 microinjector (Drummond Scientific, USA) with needles pulled from 3-000-203-G/X Glass
449 Capillaries (Drummond Scientific, USA) with a P-1000 Micropipette Puller (Sutter Instruments,
450 USA) with settings "heat: 500, pull: 60, velocity: 70, delay: 200, pressure: 500, Ramp: 490".
451 Needles were sharpened with a BV-10 Micropipette Beveler (Sutter Instruments, USA; 15°
452 angles). Each female was injected with 3 nl near the third pair of legs. After injection, mites
453 were allowed to recover on detached bean leaves on wet cotton.

454 Four days after injection, 50-100 mites surviving the injection of dsRNA against HR96-LBD
455 genes (treatment) or GFP (control) were collected with four biological replicates each. RNA
456 was extracted and sequenced as described in section 2.6.1. Prior to RNAseq, the efficiency of

457 the RNAi knockdown of each of four HR96 genes in the mix (*tetur03g00690*, *tetur03g00710*,
458 *tetur03g00730* and *tetur03g00740*) was assessed by RT-qPCR using three replicates with
459 specific primer pairs for each of the respective HR96-LDB genes (**Supplementary Table 1**).
460 Synthesis of cDNA was performed using the Maxima First Strand cDNA Synthesis Kit
461 (Thermo Fischer Scientific, USA) with RT-qPCR reactions conducted using the GoTaq® qPCR
462 Master Mix (Promega, USA) in a Mx3005P qPCR machine (Agilent Technologies, Belgium).
463 Cycle conditions were 95 °C for 10 min followed by 40 cycles of 95 °C for 15 s, 55°C for 30 s,
464 and 60 °C for 30 s, followed by a melting curve analysis step. The quality of the qPCR
465 experiments, i.e. the absence of contamination and the specificity of the primer-pairs, was
466 verified using no-template controls and melting curves, respectively. The program qbase+
467 (Biogazelle, Belgium) was used for the analysis of raw quantification cycle (Cq) values, which
468 were all first normalized against the housekeeping genes ribosomal protein 49 (*Rp49*,
469 *tetur18g03590*) and ubiquitin C (*UBQ*, *tetur03g06910*). Two technical replicates were used for
470 each biological replicate, and mean relative expression values relative to the GFP-injected strain
471 were presented with their standard deviations. Statistically significant differences between
472 treatment groups were assessed using unpaired t-tests with Benjamini-Hochberg correction for
473 multiple testing. Genome-wide differentially expressed genes between the treatment and
474 control groups were determined with RNAseq and DESeq2 as described in section 2.6.4.

475 **3 Results**

476 **3.1 Amitraz, chlorfenapyr and tralopyril resistance levels**

477 Susceptibility levels of all strains are given in **Table 1**. The populations ROS-ITi and JW were
478 susceptible to amitraz and chlorfenapyr. Resistance levels in the field collected strain HP
479 reached 7.5-fold for amitraz and 8.4-fold for chlorfenapyr, confirming an earlier study (Simma
480 et al., 2020). Further selection of the HP strain in the laboratory-selected with chlorfenapyr and
481 amitraz, resulted in strains HPC and HPA, respectively. Chlorfenapyr selection dramatically
482 increased RRs of chlorfenapyr from 8.4-fold in HP to >1500-fold in HPC, whereas amitraz-
483 selection only resulted in a more moderate increase of amitraz RRs from 7.5-fold in HP to 51-
484 fold in HPA. Remarkably, amitraz selection also resulted in mild increase of chlorfenapyr
485 resistance (RRs 8.4-fold and 49-fold in HP and HPA respectively) but chlorfenapyr selection
486 did not increase amitraz resistance (RRs 7.5-fold and 7-fold in HP and HPC, respectively).
487 When comparing the chlorfenapyr resistance levels between HPC and JW to those of tralopyril,
488 a significant decrease in RRs was observed from 1500-fold to 23-fold (**Table 1**).

489 **3.2 Mode of inheritance of chlorfenapyr resistance**

490 The chlorfenapyr mortality-response curves of F₁ females from reciprocal crosses HPC ♀ ×
491 LON ♂ (RS) and LON ♀ × HPC ♂ (SR) were nearly identical which indicated that the
492 resistance trait inherits autosomal and partly dominant (**Supplementary Figure 1,**
493 **Supplementary Table 2**). The chlorfenapyr mortality-response curve of F₂ females from the
494 (LON ♀ × HPC ♂) ♀ × LON ♂ backcross (SR × S) is shown in **Supplementary Figure 1**. A
495 χ^2 goodness-of-fit test showed that the observed mortality for SR×S was significantly different
496 from the expected mortality for monogenic inheritance ($\chi^2 = 75.75$, $df = 13$, $P < 0.05$).
497 However, in the F₂ mortality curve a clear ‘plateau’ was visible around 55% mortality and the
498 curve matched closely with the expected values for monogenic inheritance for most points
499 (**Supplementary Table 2**).

500 **3.3 Effect of synergists PBO, DEF and DEM on toxicity**

501 The toxicity of amitraz and chlorfenapyr to JW, HPA and HPC after pretreatment with
502 synergists PBO, DEF or DEM is presented in **Table 2**. Amitraz toxicity was synergized 3.2-
503 fold by PBO and 4.3-fold by DEF in the amitraz selected strain HPA, while DEM pretreatment
504 had no effect. Similar findings were observed for the susceptible Ethiopian strain JW, but at
505 considerably lower SRs of 1.4- and 1.2-fold for PBO and DEF, respectively. Pretreatment with
506 PBO, DEF or DEM only slightly enhanced the toxicity of chlorfenapyr in the chlorfenapyr
507 selected strain HPC with synergism ratios higher than 1.7-, 2.2- and 1.7-fold, respectively.
508 Conversely, pretreatment with PBO caused a small antagonistic effect on the chlorfenapyr
509 susceptible strain JW with SR of 0.85-fold. Pretreatment with DEM did not synergize the
510 toxicity of chlorfenapyr in JW.

511 **3.4 RNAseq analysis**

512 3.4.1. Genome-wide transcriptional differences and clustering

513 To investigate the genome-wide expression changes associated with chlorfenapyr and amitraz
514 resistance, a differential expression analysis was performed using a panel of strains. The
515 susceptible Ethiopian strain JW, the field collected parental HP and the laboratory-selected
516 amitraz- and chlorfenapyr resistant populations (HPA, HPC). The HPA and HPC were also
517 analyzed when continuously exposed to chlorfenapyr and amitraz (HPA_{exp} and HPC_{exp}). The
518 LON strain was used as a general reference. Illumina sequencing generated 31.145 million
519 strand-specific paired-end reads per sample, of which an average of 84% mapped uniquely

520 against the *T. urticae* three chromosome reference assembly (**Supplementary Table 3**). RNA
521 reads were submitted in the NCBI Sequence Read Archive under Bioproject (PRJNA1033836)
522 and raw read count data was made available on Figshare (DOI 10.6084/m9.figshare.24499732).
523 A PCA was performed using normalized read-counts of the 5000 most variable genes of the
524 complete dataset (**Figure 1A**). This PCA revealed that PC1, which explains the largest fraction
525 of the variance in the dataset (45%), separates JW from all other strains. PC2, which explains
526 26% of the variance in the dataset, separates all strains with Ethiopian origin from LON. The
527 PCA in **Figure 1A** also indicates a larger genome-wide transcriptional effect of amitraz
528 selection compared to chlorfenapyr because the samples of HPC, HPCexp and HP cluster
529 closely together. The variance and clustering of the selected HP subpopulations was also
530 investigated in PCA using normalized read-counts of the 5000 most variable genes of HP, HPA,
531 HPC, HPAexp and HPCexp (**Supplementary figure 2**). From this PCA it was immediately
532 clear that replicate 1 of HPC did not cluster with the other replicates and was an outlier which
533 had to be removed for further analysis. The PCA excluding this replicate is presented in **Figure**
534 **1B** and shows clear separation of all sample groups. Interestingly, as PC1 accounts for 53% of
535 the total variance in the dataset and PC2 for only 14%, the amitraz-selected populations
536 clustered further away from the parental strain HP than the chlorfenapyr-selected populations.
537 Although the treated and untreated populations still cluster together, to overall effect of
538 induction by the respective chemicals is limited, compared to strains of different genetic origin.

539 To gain better insights into the global transcriptomic patterns, a k-means clustering analysis
540 was performed, using z-scaled normalized read-counts of all genes that show significant
541 differences in expression across all samples (p value < 0.001 as determined by LTR test). A
542 total of 8769 genes was grouped into an optimum of 13 clusters as determined by the gap
543 statistic (**Supplementary Table 4**). The clustered heatmap based on individual z-scores in
544 **Figure 2A** and **Supplementary Figure 3** indicates 13 distinct transcriptomic patterns. GO
545 enrichment analysis of all genes in each cluster (**Supplementary Table 5**), combined with
546 the expression patterns of HP and its derived selected subpopulations, resulted in six clusters
547 (**Figure 2B**) that sparked our interest.

548 Cluster 3 contains 529 genes showing lower expression levels in JW and HP whose expression
549 increases after selection with both compounds. Many GO terms are significantly associated
550 with the genes in this cluster. The term GO:0008152 for metabolic process is the most
551 significantly enriched and contains five genes coding for UGTs. Also, many GO terms linked
552 to oxidoreductase activity (GO:0055114, GO:0016491, GO:0016620) are enriched, containing

553 P450s of the CYP385, CYP387 and CYP389 family and *CYP392E10*, as well as multiple SDR
554 genes. Interestingly, this cluster also contains seven genes coding for ABC transporters which
555 lead to two terms linked to increased transporter activity to be significantly enriched
556 (GO:0055085; “*transmembrane transport*” and GO:0005215; “*transporter activity*”). Cluster 5
557 contains 512 genes with specifically low expression levels in HPA whereas transcriptomic
558 levels in all other groups remain comparable. In this cluster only two GO terms are significantly
559 enriched; GO:0003676, containing a multitude of genes coding for Zinc Finger proteins
560 involved in nucleic acid binding and GO:0004674 containing genes coding for proteins with
561 serine/threonine kinase activity. Cluster 8 contains 737 genes with higher expression levels in
562 HP and all selected subpopulations. However, no GO terms could be significantly linked in this
563 cluster. Cluster 9 contains 594 that are specifically overexpressed only in the amitraz-selected
564 subpopulation of HP. This cluster contains a multitude of genes belonging to different
565 detoxification gene families resulting in highly significant enrichment of their respective GO
566 terms. Terms linked to P450 activity; “*oxidation-reduction processes*” (GO:0055114), “*iron*
567 *ion binding*” (GO:0005506), “*heme-binding*” (GO:0020037), “*oxidoreductase activity, acting*
568 *on paired donors, with incorporation or reduction of molecular oxygen*” (GO:0016705) were
569 enriched with most significant adjusted *p*-values in both the “*Molecular Function*” and
570 “*Biological Processes*” categories. Hence, cluster 9 contains overall the most CYP
571 (pseudo)genes and its majority belongs to the notorious CYP392 family; e.g. *CYP392A11*
572 (*tetur03g00970*), *CYP392A12* (*tetur03g00830*), *CYP392A16* (*tetur06g04520*), *CYP392D2*
573 (*tetur03g04990*), *CYP392D8* (*tetur03g05070*), *CYP392E8* (*tetur27g01020*) and many more.
574 Other genes within this cluster linked to these GO terms are four intradiol ring-cleavage
575 dioxygenase genes *DOGs* and *Cytochrome P450 reductase (CPR)*. This cluster contains also a
576 large number UGT (15) and GST (4) genes which lead to an enrichment of terms linked to
577 “*metabolic processes*” (GO:0016999, GO:0008152), “*transferase activity, transfer of hexosyl*
578 *groups*” (GO:0016758) and “*cysteine-type peptidase activity*” (GO:0008234). However, also
579 many other cysteine peptidase genes (4 C13 legumains and 16 cathepsin L) are grouped in
580 cluster 9, adding to the high significance of “*cysteine-type endopeptidase activity*”
581 (GO:0004197) as well as “*regulation of catalytic activity*” (GO:0050790) and “*proteolysis*”
582 (GO:0006508). Last, also a highly significant enrichment of GO terms linked with
583 transmembrane transporters (GO:0055085, GO:0006810, GO:0042626) and ATPase activity
584 (GO:0042626, GO:0016887) was apparent because of the presence of 15 ABC-transporter
585 genes. Cluster 10 contains 363 genes which show high transcriptional patterns only in the HP
586 strain and is significantly linked with “*(r)RNA processing*” (GO:0006364, GO:0006396),

587 “RNA binding” (GO:0003723) and “ribosome biogenesis” (GO:0042254). Cluster 11 contains
588 512 genes and shows a similar transcriptomic pattern as cluster 9, with the exception of JW,
589 which had a low z-score in cluster 9 but a higher z-score in cluster 11. A large fraction of the
590 genes in this cluster code for ribosomal proteins associated with various translational and
591 processes which is reflected in the enriched GO terms “translation” (GO:0006412) and
592 “structural constituent of ribosome” (GO:0003735). However, also genes coding for
593 elongation factors and chaperones like *DnaJ* involved in translation elongation and protein
594 folding, respectively, are abundantly present in this cluster leading to enrichment of the
595 respective GO terms (GO:0003746, GO:0006457, GO:0051082). Finally, this cluster is also
596 enriched with genes coding for proteasome subunits linked with endopeptidase activity
597 (GO:0004298, GO:0004175) and involved in proteolysis in cellular protein catabolic processes
598 (GO:0051603).

599 3.4.2 Pairwise differential expression shows contrasting P450 expression patterns associated
600 with amitraz and chlorfenapyr selection

601 First, pairwise differential expression analysis was performed comparing JW, HP, HPA, HPC,
602 HPAexp and HPCexp with LON as a general reference strain (**Supplementary Table 6**;
603 **Supplementary Table 7**). Immediately noticeable was that the number of differentially
604 expressed genes (DEGs; $|\text{Log}_2\text{FC}| > 1$; $p \text{ adj} < 0.05$) for JW was almost double the amount of
605 DEGs in other comparisons to LON, which is also reflected in the distinct clustering of JW in
606 the PCA plot (**Figure 1**) and largely deviating z-scores in many clusters (**Figure 2**). Moreover,
607 the largest fraction of JW DEGs was downregulated, whereas for all other strains the largest
608 fraction of DEGs was upregulated. Secondly, a differential expression analysis using only HPA,
609 HPAexp, HPC and HPCexp versus the common parent HP was undertaken to specifically study
610 DEGs following amitraz- or chlorfenapyr-selection of HP. Interestingly, the transcriptomes of
611 selected populations with the same HP parental genetic background show differences in terms
612 of the number of DEGs and the proportions of up- and downregulated genes depending on
613 amitraz or chlorfenapyr selection. Amitraz selection results in a larger total number of DEGs
614 of which the largest fraction (63% and 67% for HPA and HPAexp, respectively) was
615 upregulated. In contrast, in the chlorfenapyr selected population the largest fraction of DEGs
616 was downregulated (56% and 64% for HPC and HPCexp) (**Supplementary Table 6**;
617 **Supplementary Table 7**). Next, given the overall abundance of P450 genes in clusters
618 associated with amitraz and chlorfenapyr selection (**Supplementary Table 8**), we studied the
619 transcriptional changes of P450s due to amitraz or chlorfenapyr selection of the same

620 moderately resistant parent HP more closely. Results are shown in **Figure 3** as a heatmap of
621 the Log_2FC of all full-length P450s differentially expressed (i.e. $|\text{Log}_2\text{FC}| > 1$ and $p \text{ adj} < 0.05$)
622 in at least one of the selected subpopulations. Strikingly, based on Euclidian clustering of the
623 rows of the heatmap a cluster of four P450 genes, *CYP392A11*, *CYP392D2*, *CYP392D8* and
624 *CYP392A12* showed extreme transcriptional differences; i.e. upregulation with $\text{Log}_2\text{FCs} > 4$
625 after amitraz selection and downregulation with $\text{Log}_2\text{FCs} < -2$ after chlorfenapyr selection. All
626 four of these P450 genes were present in cluster 9 of the k-means clustering analysis together
627 with many other genes linked to detoxification processes. Another cluster of P450 genes,
628 *CYP392A16*, *CYP392D6* and *CYP392A15* also showed very high upregulation upon amitraz
629 selection but did not change much upon chlorfenapyr selection. Last, *CYP392A1* is the only
630 P450 upregulated after selection with each compound.

631 **3.5 *In vitro* metabolism of amitraz and chlorfenapyr**

632 3.5.1 Heterologous expression of *T. urticae* P450s in *E. coli*

633 Five potentially interesting P450s in this study, *CYP392A16*, *CYP392A11*, *CYP392A1*,
634 *CYP392E10*, and *CYP392D8*, were co-expressed with the *T. urticae* cytochrome P450
635 reductase (CPR) in *E.coli* membranes, producing catalytically active monooxygenase
636 complexes (Omura and Sato, 1964). All membrane preps produced showed the characteristic
637 CO-reduced spectrum, which is indicative of an active P450 (**Supplementary Table 9**). In all
638 cases, CPR activity against cytochrome c was confirmed, as shown in **Supplementary Table**
639 **9**.

640 3.5.2 *CYP392A16*-mediated hydroxylation of amitraz

641 All five P450s were evaluated for their potential to metabolize amitraz of which only
642 *CYP392A16* was able to do so. The catalytic activity of the P450 was assessed by measuring
643 amitraz turnover in the presence and absence of NADPH and analyzing the formation of
644 metabolites. Incubation of the *CYP392A16* complex with amitraz for 15 min revealed a 55.9%
645 NADPH dependent depletion of amitraz (eluting at 15.4 min) and the parallel formation of an
646 unknown metabolite (M1, eluting at 2.17 min), as compared to the control reaction without
647 NADPH (**Supplementary Figure 4A**). The ability of *CYP392A16* to metabolize amitraz was
648 further characterized by measuring substrate-depletion based reaction rates revealed Michaelis-
649 Menten kinetics (R^2 of fitted curve = 0.98, **Supplementary Figure 4B**): $K_{\text{cat}} = 36.5 (\pm 2.6 \text{ SE})$
650 pmol of depleted amitraz/min/pmol P450, $V_{\text{max}} = 182.4 (\pm 8.7 \text{ SE})$ pmol of depleted

651 amitraz/min and $K_m = 28.64 (\pm 3.97 \text{ SE}) \mu\text{M}$. CYP392A16 did not metabolize DMPF, as no
652 substrate depletion was detected (data not shown).

653 HPLC-MS and MS/MS analysis of the reaction mixtures pointed towards hydroxylation of
654 amitraz as the most likely reaction mechanism catalyzed by CYP392A16. However, neither the
655 toxic metabolite of amitraz, DMPF (N-Methyl-N'-(2,4-xylyl) formamidine) nor the other
656 known metabolites of amitraz (Giorgini et al., 2023; Guo et al., 2021; Schuntner and Thompson,
657 1978), DMF (2,4 dimethylformamide) and the DMA (2,4 dimethylaniline) could be detected.
658 Nevertheless, the accurate mass HPLC-MS analysis confirmed the generation of hydroxyl-
659 amitraz, as the major detectable metabolite M1 (**Figure 4A/B**). The positive ion mode mass
660 spectrum of the amitraz metabolite M1 showed the molecular ion peak at $m/z [M+H]^+ =$
661 310.1910, which is 15.99 Da units higher than the corresponding peak in the spectrum of the
662 parent compound at $m/z [M+ H]^+ = 294.1961$. Accurate mass measurements showed that the
663 +15.99 Da corresponds to an O atom. Thus, the metabolite has been hydroxylated, with several
664 hydroxylation sites being possible, according to the Biotransformer (v.3.0) theoretical tool
665 (**Figure 4C**). The fragmentation pattern from the MS/MS spectra of amitraz and its metabolite
666 also showed a shift upwards by 15.99 Da in the corresponding M1 metabolite product ions
667 (**Supplementary Figure 5**), which confirmed also hydroxylation as the likely mechanism of
668 the reaction catalyzed by CYP392A16, but cannot propose a specific structure for the
669 hydroxylated metabolite of amitraz.

670 3.5.3 CYP392D8-mediated activation of the pro-insecticide chlorfenapyr to its toxic N-
671 dealkylated metabolite tralopyril

672 All five P450s were also tested for their potential role to metabolize or activate the pro-
673 insecticide chlorfenapyr. Results from HPLC chromatograms in **Figure 5A** show that only
674 CYP392D8 causes an NADPH-dependent depletion of chlorfenapyr eluting at 3.96 min and the
675 formation of a metabolite eluting at 2.87 min. This metabolite corresponds possibly to the n-
676 dealkylated metabolite tralopyril (the active toxophore of chlorfenapyr), as indicated by the
677 same eluting time with standard tralopyril. For further confirmation we proceeded to LC-MS
678 analysis. Chlorfenapyr and tralopyril were detected in negative ion mode, and not in the
679 protonated molecular ion form, due to the loss of the N-ethoxymethyl group, when introduced
680 in the ESI source. Thus, although chlorfenapyr and tralopyril have the same mass spectra
681 (**Figure 5B**), they have different elution times (**Figure 5A**), so we confirmed that the formatted
682 metabolite corresponds to tralopyril.

683 3.6 Genetic mapping of chlorfenapyr and amitraz resistance

684 3.6.1. Experimental evolution and phenotyping

685 The mapping study was started from a cross between a single haploid HPC male and females of
686 the susceptible inbred strain ROS-ITi. Interestingly, HPC not only showed extremely high
687 resistance levels for chlorfenapyr after chlorfenapyr selection ($RR > 1500$), but residual amitraz
688 resistance ($RR 7.0$) was still present, which allowed to also select for amitraz resistance in the
689 mapping population. After approximately 25 generations of treatment with increasing doses of
690 chlorfenapyr or amitraz, both selected and unselected populations were phenotyped using dose-
691 response bioassays. At a dose of 500 mg L^{-1} , both acaricide-selected populations showed
692 significantly lower mortality rates compared to the control populations ($p < 0.001$, generalized
693 mixed model) (**Figure 6A,B**). Interestingly, mortality rates of chlorfenapyr in the unselected
694 samples do not show a dose-response relationship at doses between $20\text{-}2500 \text{ mg L}^{-1}$ for
695 chlorfenapyr, thus indicating segregation of a few major resistance alleles in the control
696 populations, whereas for amitraz at 1000 mg L^{-1} mortality of the control populations is at 100%
697 (**Supplementary Figure 6**).

698 3.6.2 Genetic mapping with bulked segregant analysis

699 Genomic DNA was extracted and sequenced and reads of all segregating populations and both
700 parental strains (HPC and ROS-ITi) were aligned to the *T. urticae* reference genome (Grbić et
701 al., 2011; Wybouw et al., 2019) resulting in a genomic VCF (gVCF) file containing 1,934,859
702 segregating high-quality SNPs distinguishing HPC from ROS-ITi. This gVCF was used for a
703 principal component analysis (PCA) which showed grouping of the selected and control
704 populations into distinct clusters (**Figure 6C**). To identify the genomic regions underlying
705 chlorfenapyr and amitraz resistance, a bulked segregant analysis approach was used as
706 described by [Kurlovs et al. \(2019\)](#). Briefly, this method used genome-wide differences in allele
707 frequencies at high quality SNP loci between selected and control populations (**see gVCF**
708 **available as Data S1 on Figshare: 10.6084/m9.figshare.24499732**). QTL significance was
709 determined with a permutation-based approach as described by [Snoeck et al. \(2019\)](#). Using a
710 false discovery rate (FDR) of 5%, a significantly overlapping major QTL peak could be
711 identified on chromosome 1 (hereafter QTL1) for both the amitraz and chlorfenapyr BSA
712 studies (**Figure 7A**). Interestingly, in the peak region spanning QTL1 ($\sim 20.850 \text{ Mb}$), nearly
713 complete fixation of the MPC haplotype occurred in all amitraz-selected and chlorfenapyr-
714 selected populations (**Supplementary Figure 7**). Based on the average difference in allele

715 frequencies between selected and unselected populations, there is a remarkable overlap of
716 QTL1 in both BSA studies (**Figure 7A**). However, when considering the chromosomal
717 locations of the actual peak maxima of both BSA's (~20.558 Mb for amitraz, ~21.108 Mb for
718 chlorfenapyr), the averages are 500 kb away from each other (**Figure 7B**) and the individual
719 replicability of the amitraz-selected population-pairs is lower. This has to be interpreted with
720 caution, as there is a region in the peak where the differences in allele-frequencies drops down
721 to zero, which is probably due to structural variability or misassembly in the *T. urticae* reference
722 genome. As this makes it difficult to pinpoint the absolute maximum of the overlapping QTL
723 peak, we further studied the broad genomic region surrounding the maxima of both BSA's
724 (20.458 – 21.208 Mb) covering a region of 231 genes (**Supplementary Table 10**). Within the
725 QTL1 peak we took a closer look at three interesting regions as outlined in **Figure 7C**. Regions
726 A and C represent a 50 kb window surrounding the QTL1 peak maximum of the amitraz and
727 chlorfenapyr BSA, respectively. Region B, on the other hand, is a region located around 20.9
728 Mb which contains a cluster of P450 genes and pseudogenes, similar to region C. Most of these
729 P450s belong to the CYP392A family, like CYP392A11 (*tetur03g00970*) and CYP392A12
730 (*tetur03g00830*), located in region B, which have been directly linked with resistance in *T.*
731 *urticae* before (Khalighi et al., 2016; Riga et al., 2015). However, there was no differential
732 expression between the parental strains for these two P450s, nor were there mutations enriched
733 in the selected populations. In contrast, other members of the CYP392A family located in region
734 C, like *CYP392A15* (*tetur03g09941*), *CYP392A13v1* (*tetur08g08050*) and *CYP392A13v2*
735 (*tetur03g00020*) show high levels of differential expression (Log₂FC 4.39, 2.12 and 7.21
736 respectively) in the resistant parent HPC compared to the susceptible parent ROS-ITi and have
737 several mutations enriched in the selected populations for both compounds. Apart from P450s,
738 a carboxyl/cholinesterase (CCE20, *tetur03g00310*) and a short-chain reductase
739 (*tetur03g00300*), coding for enzymes belonging to other important detoxification families, were
740 located in QTL1 region. In addition to detoxification enzymes, also a cluster of four nuclear
741 hormone receptors lacking a DNA-binding domain were found, which might play a role in *trans*
742 regulation of detoxification (**Supplementary Table 10**), as was recently shown (Ji et al., 2023;
743 Snoeck et al., 2019). The amitraz-selected populations showed two additional significant QTL
744 loci on chromosome 3; QTL2 (~3.008 Mb) and QTL3 (~17.263 Mb). Strikingly, these peaks
745 are facing downwards, which indicates that amitraz selection-pressure favors the reference
746 haplotype. Similar to QTL1, in QTL2 also multiple genes coding for P450 enzymes of the
747 CYP392A family were present, with *CYP392A10v2* (*tetur02g14400*) being the most centrally
748 located in the peak. Also four members of the gustatory receptor family as well as three

749 members of the short chain dehydrogenase/reductase family (SDRs) were present. Noteworthy,
750 one of the upregulated SDRs, *tetur02g14480*, located at ± 30 kb of the peak minimum, had two
751 missense mutations of which the allele frequency (AF) of the variant allele is lower in selected
752 populations compared to the control. The QTL3 region contains many transcriptional regulators
753 which could be linked with amitraz resistance. Amongst these we found a Myc-type, basic
754 helix-loop-helix (bHLH) domain (*tetur09g04370*), three Zinc fingers; C2H2-type
755 (*tetur09g04260*, *tetur09g04200*, *tetur09g04190*), a Myb/SANT-like DNA-binding domain
756 (*tetur09g04230*) and two eukaryotic translation initiation factors (*tetur09g92869*,
757 *tetur09g04090*). Remarkably, the two previously hypothesized target-genes of amitraz; the
758 beta-adrenergic octopamine receptor (βOAR , *tetur08g04980*) and the octopamine-tyramine
759 receptor (*tetur25g01530*), did not occur in any of the QTLs, nor were any differences in SNPs
760 in their coding sequences between selected and unselected populations.

761 **3.7 RNAi of a cluster HR96-like genes**

762 To test if the cluster of nuclear hormone genes only containing a ligand binding domain (HR96-
763 LBD) in the region of QTL1 (*tetur03g00690*, *tetur03g00710*, *tetur03g00730* and
764 *tetur03g00740*) impacts the expression levels of important detoxification genes, an RNAi
765 experiment was performed where all four of these tandem genes were knocked-down
766 simultaneously. As a control, RNAi injections were also performed with the sequence for GFP.
767 The amitraz-selected strain HPA was used for injections for practical reasons as the marker
768 P450 genes, including *CYP392A16* which has shown to be metabolically active against amitraz,
769 are upregulated in this strain. Thus, if the cluster of HR96-LBD genes are indeed the
770 transcriptional regulators, silencing them via RNAi would result in lower transcription levels
771 of the P450 genes, which is more straightforward to confirm. First, RT-qPCR was done to verify
772 the silencing efficiency of each of the four genes in the HR96-LBD cluster using gene-specific
773 primer pairs (**Supplementary Table 1**). As shown in **Supplementary Figure 8**, RT-qPCR
774 results showed that expression for each of HR96-LBD genes was reduced by ~ 41 -76%
775 following dsRNA injection as compared to the control. However, despite the trend visible for
776 *tetur03g00740*, difference in expression levels was not significant ($p > 0.05$). Also the
777 expression level of *CYP392A16* was validated following silencing of the HR96-LBD cluster
778 but no differences in expression levels were detected. Last, also RNAseq results showed very
779 little difference between the dsRNA and control datasets with resulting in high adjusted p values
780 after correction for multiple testing and only two genes surviving the statistical cutoff ($p \text{ adj} <$
781 0.05); *tetur03g00710* coding for one of the silenced HR96 genes ($\text{Log}_2\text{FC} -1.29$) and

782 *tetur05g04420* (Log₂FC -0.34) coding for a choline/ethanolaminephosphotransferase 1
783 **(Supplementary Table 11).**
784

785 4 Discussion

786 Although our understanding of acaricide and insecticide resistance in key pest species is
787 steadily increasing, the mechanisms of amitraz and chlorfenapyr resistance have remained
788 enigmatic to date, as only few studies report on incidence and molecular genetic mechanisms
789 (Chen et al., 2007; Corley et al., 2013; De Rouck et al., 2023; Takata et al., 2020; Van Leeuwen
790 et al., 2006). This is true despite the potential great economic importance of chlorfenapyr, that
791 has shown promise for control of pyrethroid-resistant malaria vectors like *A. gambiae* (Ngufor
792 et al., 2016; Tchouakui et al., 2023). Also amitraz is essential in the control of several important
793 ectoparasites, like the southern cattle tick, *R. microplus*, which poses a constant threat to
794 livestock tropical and sub-tropical regions all over the world (Jonsson, 2018). In addition,
795 amitraz is one of the few selective acaricide for in-hive use and crucial for the control of *Varroa*
796 populations in commercial beekeeping operations worldwide (Kamler et al., 2016; Rinkevich,
797 2020).

798 In a large screening study, an Ethiopian field strain of *T. urticae* (strain HP) was identified that
799 showed first evidence of moderate resistance to both chlorfenapyr and amitraz (Simma et al.,
800 2020), which prompted us to further investigate the underlying resistance mechanisms. In this
801 study we subjected the HP strain to laboratory selection with chlorfenapyr resulting in the HPC
802 strain. Toxicity assays revealed very high resistance levels (RR > 1500-fold) in HPC after only
803 a few selection cycles of HP (RR 8.4-fold), suggesting that relevant genetic variation was
804 sampled from the field. As chlorfenapyr is a pro-acaricide which needs *in vivo* oxidative
805 activation to the toxic metabolite tralopyril (Black et al., 1994), also tralopyril toxicity was
806 assessed. Toxicity bio-assays revealed a dramatic decrease in the resistance ratio for tralopyril
807 compared to chlorfenapyr (from over 1500-fold to only 23-fold, respectively) in HPC, which
808 hints towards reduced activation of the pro-acaricide as a potential resistance mechanism,
809 although other pharmacokinetic mechanisms could not be excluded. Nevertheless, activation of
810 chlorfenapyr by P450s could be inferred from synergism experiments, as toxicity was reduced
811 in the susceptible strain JW (SR 0.85-fold) after pre-treatment with PBO, most likely due to the
812 inhibition of P450-mediated oxidative removal of the chlorfenapyr *N*-ethoxymethyl group
813 which results in its active metabolite, tralopyril (Black et al., 1994). This finding is consistent
814 with studies demonstrating antagonism between PBO and chlorfenapyr in various insects and
815 mites (Ahmed and Vogel, 2015; Ohnuki et al., 2023; Raghavendra et al., 2011a, 2011b; Ullah
816 et al., 2016; Wang et al., 2019). However, PBO exhibited a minor synergistic effect in the
817 resistant strain HPC rather than an antagonistic effect. One potential explanation of this

818 observation could be that in the resistant strain the expression of relevant activating P450s is
819 already low. This would prohibit metabolic activation to tralopyril and mask the antagonistic
820 effect of PBO in toxicity. In term, the limited synergistic effects observed could indicate the
821 involvement of P450s that detoxify chlorfenapyr as a minor mechanism. Noteworthy,
822 synergism experiments also revealed a minor synergistic effect of DEF and DEM in the
823 resistant strain (SR 2.2 and 1.7, respectively), also implying that additional detoxification
824 mechanisms, next to decreased activation, are potentially involved. With the intention to
825 identify specific candidate genes linked with these hypothesis of resistance mechanisms, we
826 conducted a comprehensive genome-wide RNAseq based transcriptomic study. Differential
827 expression analysis between the chlorfenapyr-selected strain HPC and the parental strain HP
828 showed that a cluster of P450s - *CYP392A11*, *CYP392A12*, *CYP392D2* and *CYP392D8* - were
829 largely downregulated, which is a striking result as numerous studies have linked
830 overexpression of these P450s with resistance against various acaricidal compounds (Dermauw
831 et al., 2013; Khalighi et al., 2016; Piraneo et al., 2015; Riga et al., 2014; Xu et al., 2021). All
832 four P450s belong to the notorious CYP392 subfamily, that underwent a spider mite-specific
833 expansion (Dermauw et al., 2020b; Grbić et al., 2011) and of which many members have been
834 shown to metabolize acaricides in *T. urticae* (For a review, see De Rouck et al., 2023).
835 Downregulation associated with resistance also stood out from the genome-wide k-means
836 clustering analysis, as cluster 9 contains a multitude of genes belonging to the important
837 detoxification gene families of the UGTs, GSTs, P450s as well as many ABC-transporters. Of
838 all clusters, cluster 9 also contained the most P450s belonging to the CYP392 subfamily,
839 including *CYP392A11*, *CYP392A12*, *CYP392D2* and *CYP392D8*, which was also reflected in
840 a highly significant enrichment of many P450-activity linked GO terms. These unprecedented
841 transcriptomic patterns further strengthened our hypothesis that reduction in activation may be
842 the main resistance mechanism and is likely associated with the downregulation of specific
843 P450s. As the selection experiment has no replication, drift or a number of genes that regulate
844 these detox genes cannot be excluded, but given their high expression in numerous other strains
845 under investigation, this seems unlikely, and minimally, it can be concluded that they play no
846 active detoxification role. Therefore, to validate these findings, the downregulated candidates
847 *CYP392A11* and *CYP392D8*, were functionally expressed and tested for their ability to
848 metabolize chlorfenapyr. Functional enzymes were obtained for both P450s, but metabolism
849 assays followed by LC-MS showed that only *CYP392D8* was capable to metabolize
850 chlorfenapyr to a metabolite that was identified as tralopyril, hereby confirming that the
851 downregulated *CYP392D8* mediates activation rather than metabolism of chlorfenapyr.

852 Surprisingly, starting from the same parental origin HP, laboratory-selection with amitraz
853 (strain HPA) also lead to high resistance, but this resulted in the high overexpression of the
854 same cluster of P450 genes (*CYP392A11*, *CYP392A12*, *CYP392D2* and *CYP392D8*) with
855 $\text{Log}_2\text{FCs} > 4$ for all of them. In HPA two other P450s were amongst the highest upregulated
856 genes, *CYP392A1* and *CYP392A16*, whereas their expression levels were not influenced much
857 by chlorfenapyr selection. This is in line with our synergist data, where synergist ratios for DEF
858 and PBO indicated that esterases and P450 enzymes, respectively, likely play a significant role
859 in amitraz resistance. This highly upregulated set of P450s from the CYP392 family were also
860 tested for their ability to metabolize amitraz *in vitro*. *CYP392A16* metabolized amitraz with
861 high efficacy to a hydroxylated metabolite. Although the exact site and metabolite structure
862 could not be resolved, we confirmed that the structure is different from DPMF, the known toxic
863 metabolite of amitraz (Cai et al., 2023; Kita et al., 2017). This implies that *CYP392A16* is able
864 to metabolize amitraz, although further toxicological analysis of the metabolite is still required.

865 The strongly contrasting transcriptional response after selection on the same population with
866 amitraz and chlorfenapyr is remarkable, especially that a similar cluster of detox genes,
867 enriched in P450s responds in both opposite directions in comparison to the parental strain. It
868 seems unlikely that this could be due to selection of many cis-effects, given that selection
869 occurred in the laboratory with relatively small population size. As this suggests selection of a
870 few trans factors, as recently shown for the multi-resistant strain MR-VP (Ji et al., 2023), the
871 question remains how to identify potential genetic variation that leads to such patterns. Instead
872 of performing an expression QTL (eQTL) analysis, which requires an exceptional amount of
873 time and resources, we designed a genetic mapping study. As the chlorfenapyr resistant strain
874 HPC displays this unusual pattern of downregulated detoxification genes, and because of the
875 suggested unique mechanisms of decreased activation, we set up crosses with HPC rather than
876 with the amitraz selected HPA. To construct a mapping population, crosses were performed
877 between HPC strain and the susceptible inbred strain ROS-ITi. The resulting segregating
878 populations were exposed to increasing concentrations of chlorfenapyr in an experimental
879 evolutionary setup. Because the HPC strain was also moderately resistant to amitraz (to the
880 same extent as the parental population), we decided to also select with amitraz, as the variation
881 selected upon in HPA might still be segregating in HPC. This presented a unique opportunity
882 to simultaneously conduct BSA experiment with both compounds, although the link with gene-
883 expression is only directly relevant for HPC.

884 For both BSA experiments (chlorfenapyr and amitraz), one joint QTL peak on chromosome 1
885 (QTL1 at ~20.850 Mb) was found. For chlorfenapyr this single QTL corresponds with the
886 nearly monogenic pattern of inheritance of resistance deduced from classical genetic crosses
887 (fig). In the genomic region of QTL1, several detoxification genes are located, including P450s,
888 CCEs, and UGTs. Members of the CYP392 family were overrepresented in this region,
889 including *CYP392A11*, *CYP392A12*, *CYP392A13v1*, *CYP392A13v2*, *CYP392A14*, and
890 *CYP392A15*. *In vitro* expression showed however that *CYP392A11* was not functionally active
891 against neither acaricide. Apart from *CYP392A12*, none of the other P450s showed large
892 transcriptional differences in HPA and HPC versus HP. Nevertheless, the two P450s for which
893 functional validation suggested a role in resistance, *CYP392D8* for chlorfenapyr and
894 *CYP392A16* for amitraz, were not present at QTL1, nor were the beta-adrenergic octopamine
895 receptor (*BOAR*, *tetur08g04980*) and the octopamine-tyramine receptor (*tetur25g01530*), which
896 recent studies have provided evidence that they are the main target-site of amitraz (Chen et al.,
897 2007; Corley et al., 2013; Takata et al., 2020). Given the transcriptional patterns, and the lack
898 of a clear candidate resistance gene, we then hypothesized that genetic variation (for examples
899 multiple segregating alleles in HP) in transcriptional regulator could be responsible for the
900 expression differences and resulting resistant phenotype. Indeed, in a recent study it was shown
901 with allele-specific expression analysis, over a panel of resistant strains, that expression
902 differences of P450s was mainly due to *trans* acting factors (Kurlovs et al., 2022). In a follow-
903 up study, an extensive eQTL analysis identified variation in a duplicated HR96-related gene as
904 the main cause of expression differences of a large group of detox genes, including *CYP392A11*,
905 *CYP392A12* and *CYP392D8* (Ji et al., 2023). These genes belong to the nuclear hormone
906 receptor family (HR96), but lack a DNA-binding domain (HR96-LBD). Excitingly, a cluster of
907 genes of the same family NHR-LBD, *tetur03g00690*, *tetur03g00710*, *tetur03g00730* and
908 *tetur03g00740* were also present in QTL1 of this study. To investigate the role of these genes
909 in transcriptional regulation, we attempted to silence all four genes in an RNAi approach.
910 Despite the fact that silencing efficiencies reached 41-76%, we could not observe a significant
911 response in detoxification gene expression, which suggests that the HR96-LBD cluster located
912 at QTL1 is not the causal factor evoking the unique transcriptional patterns observed in this
913 study. Nevertheless, it is important to note that the HPA strain was used for RNAi experiments,
914 whereas HPC was used in the BSA mapping. As we want to reveal downregulation after
915 silencing HR96-LBD, a strain with high or normal expression levels is needed. However, albeit
916 HPA and HPC share a common parent showing resistance against amitraz and chlorfenapyr,
917 silencing of the HPA alleles of this cluster does not necessarily result in the same effect on gene

918 expression. Also, these HR96 genes that lack a DNA binding domain (DBD) are thought to act
919 via ligand- or LBD-dependent dimerization with canonical NHRs that contain both LBDs and
920 DBDs to impact gene expression (Reinking et al., 2005). Lastly, as we silenced all four HR96-
921 LBD simultaneously, and if some level of functional redundancy exists, there might still be
922 enough protein left that prevent clear effects on transcriptional influences at the time point of
923 expression analysis. These hurdles could be elegantly circumvented in the future by making
924 separate CRISPR/Cas9 induced knock-outs, a technique which recently has made big steps
925 forward in *T. urticae* (Dermauw et al., 2020). Taking everything into account, given that the
926 importance of the HR96-LBD cluster cannot be ruled out, we were not able to draw definite
927 conclusive about candidate resistance genes in QTL1 involved in resistance.

928 Interestingly, in the amitraz selected lines two additional sharp downward facing QTL peaks
929 on chromosome 3, QTL2 (~3.008 Mb) and QTL3 (~17.263 Mb), were observed. Such
930 downward facing QTL peaks have not been seen in spider mite BSA experiments before (Bryon
931 et al., 2017; De Beer et al., 2022b, 2022a; Demaeght et al., 2014; Snoeck et al., 2019; Sugimoto
932 et al., 2020; Van Leeuwen et al., 2012; Wybouw et al., 2019) and indicate that depletion rather
933 than enrichment of the variant alleles present in the HPC strain was favored upon selection with
934 amitraz. In our setup, where the chlorfenapyr selected strain was used for BSA with amitraz
935 selection, this potentially indicates that genetic variation selected by chlorfenapyr leads to
936 susceptibility to amitraz and is purified over the selection period. In these QTLs again many
937 genes belonging to important detox families like P450s, SDRs and cathepsins were present, but
938 importantly, also many candidate genes involved in transcription regulation (e.g. a Myc-type,
939 basic helix-loop-helix (bHLH) domain, Zinc fingers of the C2H2-type, a Myb/SANT-like
940 DNA-binding domain, and eukaryotic translation initiation factors). The intricate interplay
941 between these loci, leading to significant alterations in overall expression levels and resistance,
942 remains to be elucidated and calls for further in-depth investigation.

943 To conclude, this study reveals that laboratory selection with amitraz and chlorfenapyr, starting
944 from the same parental origin, leads to highly resistant strains to both compounds, but with
945 clearly contrasting transcriptomic profiles. Functional validation of key P450s showed that the
946 overexpressed CYP392A16 efficiently metabolizes amitraz, while the downregulated P450
947 CYP392D8 activates chlorfenapyr to its active metabolite tralopyril. The latter is potentially
948 one of the rare cases of decreased activation as a likely resistance mechanism. Genetic mapping
949 experiments revealed that resistance to chlorfenapyr and amitraz shared a single common major
950 QTL, while two additional specific QTLs were uncovered for amitraz resistance. Although

951 these QTLs revealed promising transcription factor candidates, further validation is needed to
952 dissect the role of individual genes in gene regulation.

953 **Data availability statement**

954 All the sequence data generated in this study have been submitted to the NCBI Sequence Read
955 Archive (SRA) under Bioprojects PRJNA1033836 for RNA data and PRJNA1033831 for DNA
956 data. Datasets needed to recreate the figures shown in this article have been deposited in
957 Figshare (DOI 10.6084/m9.figshare.24499732).

958 **References:**

- 959 Abbott, W.S., 1987. A method of computing the effectiveness of an insecticide. 1925. J. Am.
960 Mosq. Control Assoc. 3, 302–303.
- 961 Aguilar-Medel, S., Díaz-Gómez, O., Rodríguez-Maciel, J.C., González-Camacho, J.E., García-
962 Velasco, R., Martínez-Carrillo, J.L., Reséndiz-García, B., 2011. *Tetranychus urticae*
963 Koch resistance to acaricides in greenhouse rose production in Mexico. Southwest.
964 Entomol. 36, 363–371. <https://doi.org/10.3958/059.036.0313>
- 965 Ahmed, M.A.I., Vogel, C.F.A., 2015. Synergistic action of octopamine receptor agonists on the
966 activity of selected novel insecticides for control of dengue vector *Aedes aegypti*
967 (Diptera: Culicidae) mosquito. Pestic. Biochem. Physiol., Mode of Action of
968 Environmental Pollutants and Insecticides 120, 51–56.
969 <https://doi.org/10.1016/j.pestbp.2015.01.014>
- 970 Al-Antary, T.M., Al-Lala, M.R.K., Abdel-Wali, M.I., 2012. Residual effect of six acaricides
971 on the two spotted spider mite (*Tetranychus urticae* Koch) females on cucumber under
972 plastic houses conditions in three upper lands regions in Jordan. Adv. Environ. Biol.
973 2992–2998.
- 974 Anders, S., Pyl, P.T., Huber, W., 2015. HTSeq--a Python framework to work with high-
975 throughput sequencing data. Bioinformatics 31, 166–169.
976 <https://doi.org/10.1093/bioinformatics/btu638>
- 977 Andrews, S., 2010. FastQC: a quality control tool for high throughput sequence data.
978 <https://www.bioinformatics.babraham.ac.uk/projects/fastqc/> (accessed 1.1.22).
- 979 Baron, S., Merwe, N.A. van der, Madder, M., Maritz-Olivier, C., 2015. SNP analysis infers that
980 recombination is involved in the evolution of amitraz resistance in *Rhipicephalus*
981 *microplus*. PLOS One 10, e0131341. <https://doi.org/10.1371/journal.pone.0131341>
- 982 Black, B.C., Hollingworth, R.M., Ahammadsahib, K.I., Kukel, C.D., Donovan, S., 1994.
983 Insecticidal action and mitochondrial uncoupling activity of AC-303,630 and related
984 halogenated pyrroles. Pestic. Biochem. Physiol. 50, 115–128.
985 <https://doi.org/10.1006/pest.1994.1064>
- 986 Bryon, A., Kurlovs, A.H., Dermauw, W., Greenhalgh, R., Riga, M., Grbić, M., Tirry, L.,
987 Osakabe, M., Vontas, J., Clark, R.M., Van Leeuwen, T., 2017. Disruption of a
988 horizontally transferred phytoene desaturase abolishes carotenoid accumulation and
989 diapause in *Tetranychus urticae*. Proc. Natl. Acad. Sci. 114.
990 <https://doi.org/10.1073/pnas.1706865114>
- 991 Cai, P., Zhang, Yuanyuan, Yang, M., Zhang, C., Li, M., Xiao, W., Xu, Z., Zhang, Yongqiang,
992 2023. Target identification and acaricidal activity difference of amitraz and its
993 metabolite DPMF in *Tetranychus cinnabarinus* (Boisduval). Pest Manag. Sci. ps.7500.
994 <https://doi.org/10.1002/ps.7500>

995 Chen, A.C., He, H., Davey, R.B., 2007. Mutations in a putative octopamine receptor gene in
996 amitraz-resistant cattle ticks. *Vet. Parasitol.* 148, 379–383.
997 <https://doi.org/10.1016/j.vetpar.2007.06.026>

998 Chevillon, C., Ducornez, S., De Meeus, T., Koffi, B.B., Huguette Gaïa, Delathière, J.-M., Barré,
999 N., 2007. Accumulation of acaricide resistance mechanisms in *Rhipicephalus*
1000 (*Boophilus*) *microplus* (Acari: Ixodidae) populations from New Caledonia Island. *Vet.*
1001 *Parasitol.* 147, 276–288. <https://doi.org/10.1016/j.vetpar.2007.05.003>

1002 Cingolani, P., Patel, V.M., Coon, M., Nguyen, T., Land, S.J., Ruden, D.M., Lu, X., 2012a.
1003 Using *Drosophila melanogaster* as a model for genotoxic chemical mutational studies
1004 with a new program, SnpSift. *Front. Genet.* 3. <https://doi.org/10.3389/fgene.2012.00035>

1005 Cingolani, P., Platts, A., Wang, L.L., Coon, M., Nguyen, T., Wang, L., Land, S.J., Lu, X.,
1006 Ruden, D.M., 2012b. A program for annotating and predicting the effects of single
1007 nucleotide polymorphisms, SnpEff. *Fly* (Austin) 6, 80–92.
1008 <https://doi.org/10.4161/fly.19695>

1009 Corley, S.W., Jonsson, N.N., Piper, E.K., Cutullé, C., Stear, M.J., Seddon, J.M., 2013. Mutation
1010 in the *RmβAOR* gene is associated with amitraz resistance in the cattle tick
1011 *Rhipicephalus microplus*. *Proc. Natl. Acad. Sci.* 110, 16772–16777.
1012 <https://doi.org/10.1073/pnas.1309072110>

1013 Damalas, C.A., 2009. Understanding benefits and risks of pesticide use. *Sci. Res. Essays* 4,
1014 945–949.

1015 David, M.D., 2021. The potential of pro-insecticides for resistance management. *Pest Manag.*
1016 *Sci.* 77, 3631–3636. <https://doi.org/10.1002/ps.6369>

1017 David, M.-S., John, C.W., 2023. Arthropod pesticide resistance database | Michigan state
1018 universit. <https://www.pesticideresistance.org/> (accessed 4.18.23).

1019 De Beer, B., Vandenhole, M., Njiru, C., Spanoghe, P., Dermauw, W., Van Leeuwen, T., 2022a.
1020 High-resolution genetic mapping combined with transcriptome profiling reveals that
1021 both target-site resistance and increased detoxification confer resistance to the
1022 pyrethroid bifenthrin in the spider mite *Tetranychus urticae*. *Biology* 11, 1630.
1023 <https://doi.org/10.3390/biology11111630>

1024 De Beer, B., Villacis-Perez, E., Khalighi, M., Saalwaechter, C., Vandenhole, M., Jonckheere,
1025 W., Ismaeil, I., Geibel, S., Van Leeuwen, T., Dermauw, W., 2022b. QTL mapping
1026 suggests that both cytochrome P450-mediated detoxification and target-site resistance
1027 are involved in fenbutatin oxide resistance in *Tetranychus urticae*. *Insect Biochem. Mol.*
1028 *Biol.* 145, 103757. <https://doi.org/10.1016/j.ibmb.2022.103757>

1029 De Rouck, S., Īnak, E., Dermauw, W., Van Leeuwen, T., 2023. A review of the molecular
1030 mechanisms of acaricide resistance in mites and ticks. *Insect Biochem. Mol. Biol.*
1031 103981. <https://doi.org/10.1016/j.ibmb.2023.103981>

1032 Dekeyser, M.A., 2005. Acaricide mode of action. *Pest Manag. Sci.* 61, 103–110.
1033 <https://doi.org/10.1002/ps.994>

1034 Demaeght, P., Osborne, E.J., Odman-Naresh, J., Grbić, M., Nauen, R., Merzendorfer, H., Clark,
1035 R.M., Van Leeuwen, T., 2014. High resolution genetic mapping uncovers chitin
1036 synthase-1 as the target-site of the structurally diverse mite growth inhibitors
1037 clofentezine, hexythiazox and etoxazole in *Tetranychus urticae*. *Insect Biochem. Mol.*
1038 *Biol.* 51, 52–61. <https://doi.org/10.1016/j.ibmb.2014.05.004>

1039 Dermauw, W., Jonckheere, W., Riga, M., Livadaras, I., Vontas, J., Van Leeuwen, T., 2020a.
1040 Targeted mutagenesis using CRISPR-Cas9 in the chelicerate herbivore *Tetranychus*
1041 *urticae*. *Insect Biochem. Mol. Biol.* 120, 103347.
1042 <https://doi.org/10.1016/j.ibmb.2020.103347>

1043 Dermauw, W., Van Leeuwen, T., Feyereisen, R., 2020b. Diversity and evolution of the P450
1044 family in arthropods. *Insect Biochem. Mol. Biol.* 127, 103490.
1045 <https://doi.org/10.1016/j.ibmb.2020.103490>

1046 Dermauw, W., Wybouw, N., Rombauts, S., Menten, B., Vontas, J., Grbić, M., Clark, R.M.,
1047 Feyereisen, R., Van Leeuwen, T., 2013. A link between host plant adaptation and
1048 pesticide resistance in the polyphagous spider mite *Tetranychus urticae*. *Proc. Natl.*
1049 *Acad. Sci.* 110. <https://doi.org/10.1073/pnas.1213214110>

1050 Dobin, A., Davis, C.A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson,
1051 M., Gingeras, T.R., 2013. STAR: ultrafast universal RNA-seq aligner. *Bioinformatics*
1052 29, 15–21. <https://doi.org/10.1093/bioinformatics/bts635>

1053 Duarte, A., Pym, A., Garrood, W.T., Troczka, B.J., Zimmer, C.T., Davies, T.G.E., Nauen, R.,
1054 O'Reilly, A.O., Bass, C., 2022. P450 gene duplication and divergence led to the
1055 evolution of dual novel functions and insecticide cross-resistance in the brown
1056 planthopper *Nilaparvata lugens*. *PLOS Genet.* 18, e1010279.
1057 <https://doi.org/10.1371/journal.pgen.1010279>

1058 Ducornez, S., Barré, N., Miller, R.J., Garine-Wichatitsky, M. de, 2005. Diagnosis of amitraz
1059 resistance in *Boophilus microplus* in New Caledonia with the modified Larval Packet
1060 Test. *Vet. Parasitol.* 130, 285–292. <https://doi.org/10.1016/j.vetpar.2005.04.018>

1061 Feyereisen, R., Dermauw, W., Van Leeuwen, T., 2015. Genotype to phenotype, the molecular
1062 and physiological dimensions of resistance in arthropods. *Pestic. Biochem. Physiol.*,
1063 121, 61–77. <https://doi.org/10.1016/j.pestbp.2015.01.004>

1064 Georghiou, G.P., 1969. Genetics of resistance to insecticides in houseflies and mosquitoes. *Exp.*
1065 *Parasitol.* 26, 224–255. [https://doi.org/10.1016/0014-4894\(69\)90116-7](https://doi.org/10.1016/0014-4894(69)90116-7)

1066 Giorgini, M., Taroncher, M., Tolosa, J., Ruiz, M.-J., Rodríguez-Carrasco, Y., 2023. Amitraz
1067 and Its Metabolites: Oxidative Stress-Mediated Cytotoxicity in HepG2 Cells and Study
1068 of Their Stability and Characterization in Honey. *Antioxidants* 12, 885.
1069 <https://doi.org/10.3390/antiox12040885>

1070 Grbić, M., Van Leeuwen, T., Clark, R.M., Rombauts, S., Rouzé, P., Grbić, V., Osborne, E.J.,
1071 Dermauw, W., Thi Ngoc, P.C., Ortego, F., Hernández-Crespo, P., Diaz, I., Martinez,
1072 M., Navajas, M., Sucena, É., Magalhães, S., Nagy, L., Pace, R.M., Djuranović, S.,
1073 Smagghe, G., Iga, M., Christiaens, O., Veenstra, J.A., Ewer, J., Villalobos, R.M., Hutter,
1074 J.L., Hudson, S.D., Velez, M., Yi, S.V., Zeng, J., Pires-daSilva, A., Roch, F., Cazaux,
1075 M., Navarro, M., Zhurov, V., Acevedo, G., Bjelica, A., Fawcett, J.A., Bonnet, E.,
1076 Martens, C., Baele, G., Wissler, L., Sanchez-Rodriguez, A., Tirry, L., Blais, C.,
1077 Demeestere, K., Henz, S.R., Gregory, T.R., Mathieu, J., Verdon, L., Farinelli, L.,
1078 Schmutz, J., Lindquist, E., Feyereisen, R., Van de Peer, Y., 2011. The genome of
1079 *Tetranychus urticae* reveals herbivorous pest adaptations. *Nature* 479, 487–492.
1080 <https://doi.org/10.1038/nature10640>

1081 Guo, L., Fan, X., Qiao, X., Montell, C., Huang, J., 2021. An octopamine receptor confers
1082 selective toxicity of amitraz on honeybees and *Varroa mites*. *eLife* 10, e68268.
1083 <https://doi.org/10.7554/eLife.68268>

1084 Hahne, F., Ivanek, R., 2016. Visualizing genomic data using Gviz and bioconductor, in: Mathé,
1085 E., Davis, S. (Eds.), *Statistical Genomics: Methods and Protocols*, *Methods in*
1086 *Molecular Biology*. Springer, New York, NY, pp. 335–351.
1087 https://doi.org/10.1007/978-1-4939-3578-9_16

1088 Herron, G.A., Rophail, J., 2003. First detection of chlorfenapyr (Secure®) resistance in two-
1089 spotted spider mite (Acari: Tetranychidae) from nectarines in an Australian orchard.
1090 *Exp. Appl. Acarol.* 31, 131–134.
1091 <https://doi.org/10.1023/B:APPA.0000005112.65573.be>

1092 Hollingworth, R.M., 1976. Chemistry, biological activity, and uses of formamidine pesticides.
1093 Environ. Health Perspect. 14, 57–69. <https://doi.org/10.1289/ehp.761457>

1094 Horn, T., Boutros, M., 2010. E-RNAi: a web application for the multi-species design of RNAi
1095 reagents—2010 update. Nucleic Acids Res. 38, W332–W339.
1096 <https://doi.org/10.1093/nar/gkq317>

1097 Ji, M., Vandenhole, M., De Beer, B., De Rouck, S., Villacis-Perez, E., Feyereisen, R., Clark,
1098 R.M., Van Leeuwen, T., 2023. A nuclear receptor HR96-related gene underlies large
1099 trans-driven differences in detoxification gene expression in a generalist herbivore. Nat.
1100 Commun. 14, 4990. <https://doi.org/10.1038/s41467-023-40778-w>

1101 Jonsson, N.N., 2018. Molecular biology of amitraz resistance in cattle ticks of the genus
1102 *Rhipicephalus*. Front. Biosci. 23, 796–810. <https://doi.org/10.2741/4617>

1103 Khajehali, J., Van Nieuwenhuysse, P., Demaeght, P., Tirry, L., Van Leeuwen, T., 2011.
1104 Acaricide resistance and resistance mechanisms in *Tetranychus urticae* populations
1105 from rose greenhouses in the Netherlands. Pest Manag. Sci. 67, 1424–1433.
1106 <https://doi.org/10.1002/ps.2191>

1107 Khalighi, M., Dermauw, W., Wybouw, N., Bajda, S., Osakabe, M., Tirry, L., Van Leeuwen, T.,
1108 2016. Molecular analysis of cyenopyrafen resistance in the two-spotted spider mite
1109 *Tetranychus urticae*. Pest Manag. Sci. 72, 103–112. <https://doi.org/10.1002/ps.4071>

1110 Kita, T., Hayashi, T., Ohtani, T., Takao, H., Takasu, H., Liu, G., Ohta, H., Ozoe, F., Ozoe, Y.,
1111 2017. Amitraz and its metabolite differentially activate α - and β -adrenergic-like
1112 octopamine receptors: Amitraz actions on octopamine receptors. Pest Manag. Sci. 73,
1113 984–990. <https://doi.org/10.1002/ps.4412>

1114 Kojima, K., Schaffer, H.E., 1967. Survival process of linked mutant genes. Evolution 21, 518–
1115 531. <https://doi.org/10.2307/2406613>

1116 Kurlovs, A.H., Beer, B.D., Ji, M., Vandenhole, M., Meyer, T.D., Feyereisen, R., Clark, R.M.,
1117 Leeuwen, T.V., 2022. Trans-driven variation in expression is common among
1118 detoxification genes in the extreme generalist herbivore *Tetranychus urticae*. PLOS
1119 Genet. 18, e1010333. <https://doi.org/10.1371/journal.pgen.1010333>

1120 Kurlovs, A.H., Snoeck, S., Kosterlitz, O., Van Leeuwen, T., Clark, R.M., 2019. Trait mapping
1121 in diverse arthropods by bulked segregant analysis. Curr. Opin. Insect Sci. 36, 57–65.
1122 <https://doi.org/10.1016/j.cois.2019.08.004>

1123 Leonard, P.K., 2000. Chlorfenapyr, a novel IPM compatible resistance management tool for
1124 fruit production. Acta Hortic. 257–276.
1125 <https://doi.org/10.17660/ActaHortic.2000.525.30>

1126 Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G.,
1127 Durbin, R., 1000 Genome Project Data Processing Subgroup, 2009. The sequence
1128 alignment/map format and SAMtools. Bioinformatics 25, 2078–2079.
1129 <https://doi.org/10.1093/bioinformatics/btp352>

1130 Li, R., Wang, K., Xia, X., 2005. Resistance selection by meilingmycin and chlorfenapyr and
1131 activity changes of detoxicated enzymes in *Tetranychus urticae*. Acta Phytophylacica
1132 Sin. 32, 309–313.

1133 Love, M.I., Huber, W., Anders, S., 2014. Moderated estimation of fold change and dispersion
1134 for RNA-seq data with DESeq2. Genome Biol. 15, 550. <https://doi.org/10.1186/s13059-014-0550-8>

1135
1136 Lovell, J., Wright Jr, D., Gard, I., Miller, T., Treacy, M., Addor, R., Kamhi, V., 1990. AC
1137 303,630-An insecticide/acaricide from a novel class of chemistry. Presented at the
1138 Brighton Crop Protection Conference, Pests and Diseases-1990. Vol. 1., British Crop
1139 Protection Council, pp. 43–48.

- 1140 Lück, S., Kreszies, T., Strickert, M., Schweizer, P., Kuhlmann, M., Douchkov, D., 2019.
1141 siRNA-finder (si-Fi) software for RNAi-target design and off-target prediction. *Front.*
1142 *Plant Sci.* 10, 1023. <https://doi.org/10.3389/fpls.2019.01023>
- 1143 Migeon, A., Nouguier, E., Dorkeld, F., 2010. Spider mites web: a comprehensive database for
1144 the Tetranychidae, in: Sabelis, M.W., Bruin, J. (Eds.), *Trends in Acarology*. Springer
1145 Netherlands, Dordrecht, pp. 557–560. https://doi.org/10.1007/978-90-481-9837-5_96
- 1146 Ngufor, C., Critchley, J., Fagbohoun, J., N'Guessan, R., Todjinou, D., Rowland, M., 2016.
1147 Chlorfenapyr (A Pyrrole Insecticide) Applied Alone or as a Mixture with Alpha-
1148 Cypermethrin for Indoor Residual Spraying against Pyrethroid Resistant *Anopheles*
1149 *gambiae* sl: An Experimental Hut Study in Cove, Benin. *PLOS ONE* 11, e0162210.
1150 <https://doi.org/10.1371/journal.pone.0162210>
- 1151 Nicastro, R.L., Sato, M.E., Arthur, V., da Silva, M.Z., 2013. Chlorfenapyr resistance in the
1152 spider mite *Tetranychus urticae*: stability, cross-resistance and monitoring of resistance.
1153 *Phytoparasitica* 41, 503–513. <https://doi.org/10.1007/s12600-013-0309-x>
- 1154 Ohnuki, S., Osawa, Y., Matsumoto, T., Tokishita, S., Fujiwara, S., 2023. Utilization of
1155 piperonyl butoxide and 1-aminobenzotriazole for metabolic studies of toxic chemicals
1156 in *Daphnia magna* and *Chironomus yoshimatsui*. *Ecotoxicology* 32, 25–37.
1157 <https://doi.org/10.1007/s10646-022-02617-4>
- 1158 Omura, T., Sato, R., 1964. The carbon monoxide-binding pigment of liver microsomes: I
1159 evidence for its hemoprotein nature. *J. Biol. Chem.* 239, 2370–2378.
- 1160 Pimprale, S.S., Besco, C.L., Bryson, P.K., Brown, T.M., 1997. Increased susceptibility of
1161 pyrethroid-resistant tobacco budworm (Lepidoptera: Noctuidae) to chlorfenapyr. *J.*
1162 *Econ. Entomol.* 90, 49–54.
- 1163 Piraneo, T.G., Bull, J., Morales, M.A., Lavine, L.C., Walsh, D.B., Zhu, F., 2015. Molecular
1164 mechanisms of *Tetranychus urticae* chemical adaptation in hop fields. *Sci. Rep.* 5,
1165 17090. <https://doi.org/10.1038/srep17090>
- 1166 Raghavendra, K., Barik, T.K., Bhatt, R.M., Srivastava, H.C., Sreehari, U., Dash, A.P., 2011a.
1167 Evaluation of the pyrrole insecticide chlorfenapyr for the control of *Culex*
1168 *quinquefasciatus* Say. *Acta Trop.* 118, 50–55.
1169 <https://doi.org/10.1016/j.actatropica.2011.02.001>
- 1170 Raghavendra, K., Barik, T.K., Sharma, P., Bhatt, R.M., Srivastava, H.C., Sreehari, U., Dash,
1171 A.P., 2011b. Chlorfenapyr: a new insecticide with novel mode of action can control
1172 pyrethroid resistant malaria vectors. *Malar. J.* 10, 16. [https://doi.org/10.1186/1475-](https://doi.org/10.1186/1475-2875-10-16)
1173 [2875-10-16](https://doi.org/10.1186/1475-2875-10-16)
- 1174 Reinking, J., Lam, M.M.S., Pardee, K., Sampson, H.M., Liu, S., Yang, P., Williams, S., White,
1175 W., Lajoie, G., Edwards, A., Krause, H.M., 2005. The *Drosophila* Nuclear Receptor
1176 E75 Contains Heme and Is Gas Responsive. *Cell* 122, 195–207.
1177 <https://doi.org/10.1016/j.cell.2005.07.005>
- 1178 Riga, M., Bajda, S., Themistokleous, C., Papadaki, S., Palzewicz, M., Dermauw, W., Vontas,
1179 J., Leeuwen, T.V., 2017. The relative contribution of target-site mutations in complex
1180 acaricide resistant phenotypes as assessed by marker assisted backcrossing in
1181 *Tetranychus urticae*. *Sci. Rep.* 7, 9202. <https://doi.org/10.1038/s41598-017-09054-y>
- 1182 Riga, M., Myridakis, A., Tsakireli, D., Morou, E., Stephanou, E.G., Nauen, R., Van Leeuwen,
1183 T., Douris, V., Vontas, J., 2015. Functional characterization of the *Tetranychus urticae*
1184 *CYP392A11*, a cytochrome P450 that hydroxylates the METI acaricides cyenopyrafen
1185 and fenpyroximate. *Insect Biochem. Mol. Biol.* 65, 91–99.
1186 <https://doi.org/10.1016/j.ibmb.2015.09.004>
- 1187 Riga, M., Tsakireli, D., Ilias, A., Morou, E., Myridakis, A., Stephanou, E.G., Nauen, R.,
1188 Dermauw, W., Van Leeuwen, T., Paine, M., Vontas, J., 2014. Abamectin is metabolized
1189 by CYP392A16, a cytochrome P450 associated with high levels of acaricide resistance

1190 in *Tetranychus urticae*. Insect Biochem. Mol. Biol. 46, 43–53.
1191 <https://doi.org/10.1016/j.ibmb.2014.01.006>

1192 Russell, D.W., Sambrook, J., 2001. Molecular cloning: a laboratory manual. Cold Spring
1193 Harbor Laboratory Cold Spring Harbor, NY.

1194 Schuntner, C.A., Thompson, P.G., 1978. Metabolism of [¹⁴C]amitraz in larvae of *Boophilus*
1195 *microplus*. Aust. J. Biol. Sci. 31, 141–148. <https://doi.org/10.1071/bi9780141>

1196 Sheppard, C.D., Joyce, J.A., 1998. Increased susceptibility of pyrethroid-resistant horn flies
1197 (Diptera: Muscidae) to chlorfenapyr. J. Econ. Entomol. 91, 398–400.

1198 Simma, E.A., Hailu, B., Jonckheere, W., Rogiers, C., Duchateau, L., Dermauw, W., Van
1199 Leeuwen, T., 2020. Acaricide resistance status and identification of resistance mutations
1200 in populations of the two-spotted spider mite *Tetranychus urticae* from Ethiopia. Exp.
1201 Appl. Acarol. 82, 475–491. <https://doi.org/10.1007/s10493-020-00567-2>

1202 Smith, J.M., Haigh, J., 1974. The hitch-hiking effect of a favourable gene. Genet. Res. 23, 23–
1203 35. <https://doi.org/10.1017/S0016672300014634>

1204 Snoeck, S., Greenhalgh, R., Tirry, L., Clark, R.M., Van Leeuwen, T., Dermauw, W., 2017. The
1205 effect of insecticide synergist treatment on genome-wide gene expression in a
1206 polyphagous pest. Sci. Rep. 7, 13440. <https://doi.org/10.1038/s41598-017-13397-x>

1207 Snoeck, S., Kurlovs, A.H., Bajda, S., Feyereisen, R., Greenhalgh, R., Villacis-Perez, E.,
1208 Kosterlitz, O., Dermauw, W., Clark, R.M., Van Leeuwen, T., 2019. High-resolution
1209 QTL mapping in *Tetranychus urticae* reveals acaricide-specific responses and common
1210 target-site resistance after selection by different METI-I acaricides. Insect Biochem.
1211 Mol. Biol. 110, 19–33. <https://doi.org/10.1016/j.ibmb.2019.04.011>

1212 Sparks, T.C., 2013. Insecticide discovery: an evaluation and analysis. Pestic. Biochem. Physiol.
1213 107, 8–17. <https://doi.org/10.1016/j.pestbp.2013.05.012>

1214 Sparks, T.C., Nauen, R., 2015. IRAC: mode of action classification and insecticide resistance
1215 management. Pestic. Biochem. Physiol., Insecticide and Acaricide Modes of Action and
1216 their Role in Resistance and its Management 121, 122–128.
1217 <https://doi.org/10.1016/j.pestbp.2014.11.014>

1218 Sparks, T.C., Storer, N., Porter, A., Slater, R., Nauen, R., 2021. Insecticide resistance
1219 management and industry: the origins and evolution of the Insecticide Resistance Action
1220 Committee (IRAC) and the mode of action classification scheme. Pest Manag. Sci. 77,
1221 2609–2619. <https://doi.org/10.1002/ps.6254>

1222 Sterck, L., Billiau, K., Abeel, T., Rouzé, P., Van de Peer, Y., 2012. ORCAE: online resource
1223 for community annotation of eukaryotes. Nat. Methods 9, 1041–1041.
1224 <https://doi.org/10.1038/nmeth.2242>

1225 Stone, B.F., 1968. A formula for determining degree of dominance in cases of monofactorial
1226 inheritance of resistance to chemicals. Bull. World Health Organ. 38, 325–326.

1227 Sugimoto, N., Takahashi, A., Ihara, R., Itoh, Y., Jouraku, A., Van Leeuwen, T., Osakabe, M.,
1228 2020. QTL mapping using microsatellite linkage reveals target-site mutations
1229 associated with high levels of resistance against three mitochondrial complex II
1230 inhibitors in *Tetranychus urticae*. Insect Biochem. Mol. Biol. 123, 103410.
1231 <https://doi.org/10.1016/j.ibmb.2020.103410>

1232 Takata, M., Misato, S., Ozoe, F., Ozoe, Y., 2020. A point mutation in the β -adrenergic-like
1233 octopamine receptor: possible association with amitraz resistance. Pest Manag. Sci. 76,
1234 3720–3728. <https://doi.org/10.1002/ps.5921>

1235 Tchouakui, M., Assatse, T., Tazokong, H.R., Oruni, A., Menze, B.D., Nguiffo-Nguete, D.,
1236 Mugenzi, L.M.J., Kayondo, J., Watsenga, F., Mzilahowa, T., Osaé, M., Wondji, C.S.,
1237 2023. Detection of a reduced susceptibility to chlorfenapyr in the malaria vector
1238 *Anopheles gambiae* contrasts with full susceptibility in *Anopheles funestus* across
1239 Africa. Sci. Rep. 13, 2363. <https://doi.org/10.1038/s41598-023-29605-w>

- 1240 Terada, H., 1990. Uncouplers of oxidative phosphorylation. *Environ. Health Perspect.* 87, 213–
1241 218. <https://doi.org/10.1289/ehp.9087213>
- 1242 Tibshirani, R., Walther, G., Hastie, T., 2001. Estimating the number of clusters in a data set via
1243 the gap statistic. *J. R. Stat. Soc. Ser. B Stat. Methodol.* 63, 411–423.
1244 <https://doi.org/10.1111/1467-9868.00293>
- 1245 Ullah, S., Shah, R.M., Shad, S.A., 2016. Genetics, realized heritability and possible mechanism
1246 of chlorfenapyr resistance in *Oxycarenus hyalinipennis* (Lygaeidae: Hemiptera). *Pestic.*
1247 *Biochem. Physiol.* 133, 91–96. <https://doi.org/10.1016/j.pestbp.2016.02.007>
- 1248 Van Laecke, K., Degheele, D., 1993. Effect of insecticide—synergist combinations on the
1249 survival of *Spodoptera exigua*. *Pestic. Sci.* 37, 283–288.
1250 <https://doi.org/10.1002/ps.2780370308>
- 1251 Van Leeuwen, T., Demaeght, P., Osborne, E.J., Dermauw, W., Gohlke, S., Nauen, R., Grbić,
1252 M., Tirry, L., Merzendorfer, H., Clark, R.M., 2012. Population bulk segregant mapping
1253 uncovers resistance mutations and the mode of action of a chitin synthesis inhibitor in
1254 arthropods. *Proc. Natl. Acad. Sci.* 109, 4407–4412.
1255 <https://doi.org/10.1073/pnas.1200068109>
- 1256 Van Leeuwen, T., Dermauw, W., 2016. The molecular evolution of xenobiotic metabolism and
1257 resistance in chelicerate mites. *Annu. Rev. Entomol.* 61, 475–498.
1258 <https://doi.org/10.1146/annurev-ento-010715-023907>
- 1259 Van Leeuwen, T., Stillatus, V., Tirry, L., 2004. Genetic analysis and cross-resistance spectrum
1260 of a laboratory-selected chlorfenapyr resistant strain of two-spotted spider mite (Acari:
1261 Tetranychidae). *Exp. Appl. Acarol.* 32, 249–261.
1262 <https://doi.org/10.1023/B:APPA.0000023240.01937.6d>
- 1263 Van Leeuwen, T., Tirry, L., Yamamoto, A., Nauen, R., Dermauw, W., 2015. The economic
1264 importance of acaricides in the control of phytophagous mites and an update on recent
1265 acaricide mode of action research. *Pestic. Biochem. Physiol.*, 121, 12–21.
1266 <https://doi.org/10.1016/j.pestbp.2014.12.009>
- 1267 Van Leeuwen, T., Van Pottelberge, S., Tirry, L., 2006. Biochemical analysis of a chlorfenapyr-
1268 selected resistant strain of *Tetranychus urticae* Koch. *Pest Manag. Sci.* 62, 425–433.
1269 <https://doi.org/10.1002/ps.1183>
- 1270 Van Leeuwen, T., Van Pottelberge, S., Tirry, L., 2005. Comparative acaricide susceptibility
1271 and detoxifying enzyme activities in field-collected resistant and susceptible strains of
1272 *Tetranychus urticae*. *Pest Manag. Sci.* 61, 499–507. <https://doi.org/10.1002/ps.1001>
- 1273 Van Leeuwen, T., Vanholme, B., Van Pottelberge, S., Van Nieuwenhuysse, P., Nauen, R., Tirry,
1274 L., Denholm, I., 2008. Mitochondrial heteroplasmy and the evolution of insecticide
1275 resistance: non-Mendelian inheritance in action. *Proc. Natl. Acad. Sci.* 105, 5980–5985.
1276 <https://doi.org/10.1073/pnas.0802224105>
- 1277 Van Leeuwen, T., Vontas, J., Tsagkarakou, A., Dermauw, W., Tirry, L., 2010. Acaricide
1278 resistance mechanisms in the two-spotted spider mite *Tetranychus urticae* and other
1279 important Acari: a review. *Insect Biochem. Mol. Biol.* 40, 563–572.
1280 <https://doi.org/10.1016/j.ibmb.2010.05.008>
- 1281 Van Pottelberge, S., Van Leeuwen, T., Khajehali, J., Tirry, L., 2009. Genetic and biochemical
1282 analysis of a laboratory-selected spirodiclofen-resistant strain of *Tetranychus urticae*
1283 Koch (Acari: Tetranychidae). *Pest Manag. Sci.* 65, 358–366.
1284 <https://doi.org/10.1002/ps.1698>
- 1285 Van Pottelberge, S., Van Leeuwen, T., Van Amermaet, K., Tirry, L., 2008. Induction of
1286 cytochrome P450 monooxygenase activity in the two-spotted spider mite *Tetranychus*
1287 *urticae* and its influence on acaricide toxicity. *Pestic. Biochem. Physiol.* 91, 128–133.
1288 <https://doi.org/10.1016/j.pestbp.2008.03.005>

- 1289 Vlogiannitis, S., Mavridis, K., Dermauw, W., Snoeck, S., Katsavou, E., Morou, E., Harizanis,
1290 P., Swevers, L., Hemingway, J., Feyereisen, R., Van Leeuwen, T., Vontas, J., 2021.
1291 Reduced proinsecticide activation by cytochrome P450 confers coumaphos resistance
1292 in the major bee parasite *Varroa destructor*. *Proc. Natl. Acad. Sci.* 118, e2020380118.
1293 <https://doi.org/10.1073/pnas.2020380118>
- 1294 Wang, X., Wang, J., Cao, X., Wang, F., Yang, Y., Wu, S., Wu, Y., 2019. Long-term monitoring
1295 and characterization of resistance to chlorfenapyr in *Plutella xylostella* (Lepidoptera:
1296 Plutellidae) from China. *Pest Manag. Sci.* 75, 591–597. <https://doi.org/10.1002/ps.5222>
- 1297 Wybouw, N., Kosterlitz, O., Kurlavs, A.H., Bajda, S., Greenhalgh, R., Snoeck, S., Bui, H.,
1298 Bryon, A., Dermauw, W., Van Leeuwen, T., Clark, R.M., 2019. Long-term population
1299 studies uncover the genome structure and genetic basis of xenobiotic and host plant
1300 adaptation in the herbivore *Tetranychus urticae*. *Genetics* 211, 1409–1427.
1301 <https://doi.org/10.1534/genetics.118.301803>
- 1302 Xu, D., Zhang, Yan, Zhang, Youjun, Wu, Q., Guo, Z., Xie, W., Zhou, X., Wang, S., 2021.
1303 Transcriptome profiling and functional analysis suggest that the constitutive
1304 overexpression of four cytochrome P450s confers resistance to abamectin in
1305 *Tetranychus urticae* from China. *Pest Manag. Sci.* 77, 1204–1213.
1306 <https://doi.org/10.1002/ps.6130>

1307

1308

1309 **Acknowledgements**

1310 This work was supported by the Research Council (ERC) under the European Union's Horizon
1311 2020 research and innovation program (Grant agreement No. 772026-POLYADAPT and
1312 773902-SuperPests) to TVL and the Special Research Fund of Ghent University (grant
1313 BOFSTA2017003701) to TVL and the Research Foundation Flanders (grant G035420N) to
1314 TVL. XL and WX were the recipients of a doctoral grant from China Scholarship Council
1315 (CSC).

1316 **Author contributions**

1317 **Marilou Vandenhole**: Software, Formal analysis, Investigation, Writing (Original Draft), Data
1318 Curation, Visualization, **Xueping Lu**: Formal analysis, Investigation, Writing (Original Draft),
1319 Visualization, **Dimitra Tsakireli**: Formal analysis, Investigation, Writing (Original Draft),
1320 Visualization, **Catherine Mermans**: Formal Analysis, **Sander De Rouck**: Formal Analysis,
1321 **Berdien De Beer**: Formal Analysis, **Eba Simma**: Resources, **Spiros A. Pergantis**: Supervision,
1322 formal analysis, Methodology, **Wim Jonckheere**: Writing (Review & Editing), **John Vontas**:
1323 Supervision, Funding Acquisition, **Thomas Van Leeuwen**: Conceptualization, Methodology,
1324 Funding Acquisition, Supervision, Writing (Review & Editing).

1325 **Competing interests**

1326 The authors declare no competing interests.

1327

1328 **Main Text Tables**1329 **Table 1. LC₅₀s of amitraz, chlorfenapyr and its active metabolite tralopyril.**

strain	amitraz		chlorfenapyr		tralopyril	
	LC ₅₀ (95% CI) (mg L ⁻¹)	RR ^a (95%CI)	LC ₅₀ (95% CI) (mg L ⁻¹)	RR ^a (95%CI)	LC ₅₀ (95% CI) (mg L ⁻¹)	RR ^b (95%CI)
LON	24 (16 - 30)	1.0	6.8 (6.1 - 7.3)	1.0	-	-
ROS-ITi	36 (30 - 42)	1.5 (1.3 - 1.8)	8.2 (7.7 - 9.1)	1.2 (1.1 - 1.3)	-	-
JW	20 (12 - 30)	0.88 (0.5 - 1.3)	8.9 (8.3 - 9.2)	1.3 (1.3 - 1.4)	32 (29 - 37)	1.0
HP	180 (140 - 210)	7.5 (6.2 - 9.0)	57 (43 - 73)	8.4 (6.4 - 11)	-	-
HPA	1200 (1100 - 1300)	51 (45 - 57)	330 (270 - 410)	49 (40 - 62)	-	-
HPC	170 (140 - 190)	7.0 (6.0 - 8.1)	>10000	>1500	740 (700 - 780)	23 (21 - 25)

^aResistance ratio and corresponding 95% are calculated relative to London

^bResistance ratio and corresponding 95% are calculated relative to Jimma wild

1330

1331 **Table 2. LC₅₀s of amitraz and chlorfenapyr with and without pre-exposure to the**
 1332 **synergists PBO (1000 mg L⁻¹), DEM (2000 mg L⁻¹) or DEM (300 mg L⁻¹ for JW and 500**
 1333 **mg L⁻¹ for HPC and HPA).**


strain	synergism	amitraz		chlorfenapyr	
		LC ₅₀ (95% CI) (mg L ⁻¹)	SR ^a (95%CI)	LC ₅₀ (95% CI) (mg L ⁻¹)	SR ^a (95%CI)
JW	-	20	1.0	9.0 (9.0 - 9.1)	1.0
	PBO	15 (13 - 17)	1.4 (1.2 - 1.5)	11 (10 - 11)	0.85 (0.83 - 0.87)
	DEF	17 (15 - 19)	1.2 (1.1 - 1.3)	2.7 (1.9 - 3.4)	3.4 (2.9 - 3.8)
	DEM	20 (17 - 23)	1.0 (0.9 - 1.2)	9.0 (8.8 - 9.2)	1.0 (1.0 - 1.0)
HPA	-	1200	1.0		
	PBO	380 (330 - 430)	3.2 (2.8 - 3.7)		
	DEF	280 (240 - 320)	4.3 (3.4 - 5.0)		
	DEM	1100 (920 - 1200)	1.1 (1.0 - 1.3)		
HPC	-			> 10000	1.0
	PBO			6000 (4200 - 9800)	> 1.7
	DEF			4500 (3900 - 5100)	> 2.2
	DEM			5800 (4800 - 7500)	> 1.7

^aSynergism ratio= LC₅₀ / LC₅₀ + synergist

1334


1335

1336 **Main text figures**



1337

1338 **Figure 1. Principal component analysis (PCA) based on gene expression profiles of**
1339 **amitraz and/or chlorfenapyr resistant and susceptible strains.** A) PCA based on
1340 transcriptional differences within and between all treatment groups (LON, JW, HP, HPA,
1341 HPAexp, HPC and HPCexp). B) PCA based on transcriptional differences solely due to
1342 selection pressure within and between HP and the derived laboratory-selected amitraz- or
1343 chlorfenapyr resistant subpopulations (HPA/HPAexp and HPC/HPCexp, respectively) where
1344 HPAexp and HPCexp were kept under continuous amitraz or chlorfenapyr selection pressure.
1345 PC1 and PC2 are presented on the x- and y-axis respectively, with the percentage of variance
1346 explained by each PC shown in parenthesis. The outlier HPC replicate 1 was excluded from
1347 this and all further transcriptomic analysis.




1348

1349 **Figure 2. K-means clustering of genes based on genome wide transcriptomic differences**

1350 **between *T. urticae* strains LON, JW, HP, HPA, HPAexp, HPC and HPCexp. A) Genome-**

1351 wide heatmap of z-scores calculated from normalized read counts. Rows represent the genes
1352 that are grouped according to their respective clusters. B) the six most interesting clusters, plots
1353 were made representing the average z-score for all replicates per treatment group per gene in
1354 the cluster (grey lines), which was thereafter used to calculate the average z-score trend (black
1355 line) with standard deviation across all genes in the cluster. C) For the six clusters of panel B
1356 the enriched GO terms for Biological Processes (BP) and Molecular Functions (MF) are shown.
1357 Only the three most significant terms for each category are shown in case there were more.




1358

1359 **Figure 3. Expression heatmap of a selection of *T. urticae* P450s.** Expression heatmap of
 1360 differentially expressed full-length P450s in *T. urticae* females selected with amitraz (HPA) or

1361 chlorfenapyr (HPC) (“exp” with continuous exposure). The Log₂ Fold Changes are relative to
1362 the expression levels in the HP strain. P450s were clustered using the Euclidian distance, and
1363 P450s that were not differentially expressed ($|\text{Log}_2\text{FC}| < 1$ and/or p value > 0.05) in all four
1364 comparisons were excluded from the heatmap.


1365



1366

1367 **Figure 4. CYP392A16 metabolism of the acaricide amitraz.** A) HPLC extracted ion
 1368 chromatograms obtained using high resolution full scan MS show that CYP392A16 causes a
 1369 NADPH-dependent transformation of amitraz (eluting at 6.05 min) to a metabolite M1 (eluting
 1370 at 2.47 min). B) Accurate mass spectra obtained using HPLC - electrospray ionization. Upper
 1371 panel: High-resolution accurate mass of protonated amitraz at m/z 294.1961. Lower panel:
 1372 High-resolution accurate mass of the protonated amitraz metabolite M1 at m/z 310.1910.
 1373 Shown with their assigned elemental composition and corresponding mass accuracy. C)
 1374 Possible structures of the hydroxylated metabolite of amitraz, with according the Bio
 1375 Transformer 3.0 tool several hydroxylation sites being possible.


1376



1377

1378 **Figure 5. CYP392D8 activation of the pro-acaricide chlorfenapyr to tralopyril.** A) HPLC
 1379 extracted ion chromatograms obtained using high resolution full scan MS, show that
 1380 CYP392D8 causes a NADPH-dependent transformation of chlorfenapyr (eluting at 3.96 min)
 1381 to its toxic metabolite, tralopyril (eluting at 2.87 min). B) Accurate mass spectra obtained using
 1382 HPLC - electrospray ionization. Upper panel: High-resolution accurate mass of chlorfenapyr.
 1383 Lower panel: High-resolution accurate mass of the toxic metabolite of chlorfenapyr, tralopyril.
 1384 Chlorfenapyr and tralopyril were detected in negative ion mode, and not in the protonated
 1385 molecular ion form, due to the loss of the N-ethoxymethyl group, when introduced in the ESI
 1386 source.

1387



1388

1389 **Figure 6. Phenotypic and genomic differentiation after amitraz and chlorfenapyr selection.**

1390 A) Adult corrected mortality of long-term selected and control (unselected) populations after


1391 application of 500 mg L⁻¹ amitraz. B) Adult corrected mortality of long-term selected and

1392 control (unselected) populations after application of 500 mg L⁻¹ chlorfenapyr. C) Principal

1393 component analysis (PCA) of the unselected and selected populations of ROS-ITi X HPC cross

1394 based on genome-wide allele frequencies at polymorphic sites. The PCA clearly separates the

1395 amitraz-selected from the chlorfenapyr-selected and unselected populations.



1396

1397 **Figure 7. Genomic responses to amitraz and chlorfenapyr selection in the chlorfenapyr**

1398 **selected strain (HPC) based QTL mapping.** A) Averaged genome-wide change in allele

1399 frequency using ten chlorfenapyr selected sub-populations (red) and ten amitraz selected sub-

1400 populations (blue) compared to their paired unselected controls, originating from HPC. Dashed

1401 red (chlorfenapyr) and blue (amitraz) lines delineate statistical significance for QTL detection

1402 (FDR of 5%). For both QTL mapping experiments, one mutual QTL on chromosome 1

1403 exceeded the 5% FDR threshold; QTL1 at ~20.85 Mb. For the amitraz two extra downward

1404 facing QTLs on chromosome 3 were detected that exceeded the 5% FDR threshold; QTL2 at


1405 ~3.008 Mb and QTL3 at ~17.263 Mb. Chromosomes are ordered by decreasing length and are

1406 indicated by alternating shading. B) Chromosome location of QTL1 peaks (left), QTL2 peaks

1407 (middle) and QTL3 peaks (right) for each replicate of BSA chlorfenapyr (red) and BSA amitraz

1408 (blue). Chromosome location of average of each QTL peak calculated by combining all
1409 replicates into a single analysis (see panel A) are indicated with a solid square, while QTL peaks
1410 of single replicates are indicated with a solid circle. C) graphical representation of genes within
1411 interesting regions of QTL1. Regions A and C represent a 50 kb window surrounding the QTL1
1412 peak maximum of the amitraz and chlorfenapyr BSA, respectively. Region B, on the other hand,
1413 is a region located around 20.9 Mb which contains a cluster of P450 genes and pseudogenes
1414 (highlighted in orange) and a cluster of HR96-LBD genes (highlighted in green).


1415



1417

1418 **Supplementary Figure 1: Chlorfenapyr has as monogenic basis in HPC.** Concentration-
 1419 mortality curves for chlorfenapyr in strains HPC (●), LON (○), the reciprocal crosses HPC x
 1420 LON (▼) and LON x HPC (△), the (LON x HPC)F1 x LON backcross (□) and the theoretical
 1421 backcross based on monogenic inheritance (■)


1422



1423

1424 **Supplementary Figure 2. Principal component analysis (PCA) to identify the outlier in**
 1425 **the dataset.** PCA based on transcriptional differences within and between HP and the derived
 1426 laboratory-selected amitraz- or chlorfenapyr resistant subpopulations (HPA/HPAexp and
 1427 HPC/HPCexp, respectively) identifying HPC replicate 1 to be an outlier and thus to be excluded
 1428 from all further transcriptomic analysis. PC1 and PC2 are presented on the x- and y-axis
 1429 respectively, with the percentage of variance explained by each PC shown in parenthesis.


1430



1431

1432 **Supplementary Figure 3. Z-scores of all genes within each cluster of *T. urticae* strains**
 1433 **LON, JW, HP, HPA, HPAexp, HPC and HPCexp.** For each cluster, plots were made
 1434 representing the average z-score for all replicates per treatment group per gene in the cluster
 1435 (grey lines), which was thereafter used to calculate the average z-score trend (black line) with
 1436 standard deviation across all genes in the cluster.


1437



1438

1439 **Supplementary Figure 4. CYP392A16 activity towards the acaricide amitraz.** A) HPLC
 1440 chromatograms show a NADPH-dependent depletion of the acaricide amitraz (eluting at 15.4
 1441 min) and the corresponding formation of an unknown metabolite (eluting at 2.17 min).
 1442 Absorbance curves are plotted in blue. B) Michaelis–Menten kinetics of the depletion of amitraz
 1443 by CYP392A16. Plotted values represent the mean. The curve was calculated by non-linear
 1444 regression.


1445



1446

1447 **Supplementary Figure 5. Parallel reaction monitoring of the protonated amitraz (upper**
 1448 **panel) and its metabolite, M1, proposed to be hydroxyl-amitraz, (lower panel).** The product
 1449 ions for amitraz precursor ions; A) m/z 163.1228 and B) m/z 253.1700 and product ions of
 1450 metabolite M1 precursor ions C) m/z 179.1179 and D) m/z 269.1647. occur a mass difference
 1451 of +15.99 Da between the parental amitraz and its metabolite M1. This is reflected in the amitraz
 1452 (A and B) and M1 metabolite (C and D) product ions formed by collision induced dissociation
 1453 as they have a 15.99 Da difference (A $\xrightarrow{+15.99}$ C, B $\xrightarrow{+15.99}$ D), supporting that hydroxylation as
 1454 the main mechanism.

1455




1456

1457 **Supplementary Figure 6. Phenotypic response after amitraz and chlorfenapyr selection.**

1458 Other doses tested than Figure 6A. Adult corrected mortality of long-term selected and control
1459 (unselected) populations after application of 50, 100 or 1000 mg L⁻¹ amitraz or 10, 100 and
1460 2500 mg L⁻¹ chlorfenapyr.


1461



1462

1463 **Supplementary Figure 7. BSA allele frequencies of individual replicates.** Deviations in
 1464 allele frequencies of amitraz selected (AMI), chlorfenapyr selected (CFP) and unselected
 1465 (control, CON) populations of BSA amitraz and BSA chlorfenapyr.

1466



1467

1468 **Supplementary Figure 8. Silencing efficiency of HR96-LDB cluster after RNAi.** Relative
 1469 expression levels of the HR96-LDB cluster (*tetur03g00690*, *tetur03g00710*, *tetur03g00730* and
 1470 *tetur03g00740*) determined by RT-qPCR after injection with HR96-dsRNA or GFP-dsRNA as
 1471 a control. Expression levels are scaled to the mean of the control in each experiment. For the
 1472 bar plot, means (n=3), error bars of ± 1 standard deviation, and all data points are shown.
 1473 Statistical insignificances were observed using t-tests with Benjamini-Hochberg correction (n.s.,
 1474 not significant; $p \text{ adj} < 0.05^*$, $p \text{ adj} < 0.01^{**}$, and $p \text{ adj} < 0.001^{***}$).

1475

1476 **Supplementary Table Information**

1477 **Supplementary Table 1.** Primers used for RT-qPCR for genes listed in column “Target” and
1478 amplification of products for use in dsRNA production against HR96-LBD genes and GFP
1479 (column “Target”). In the primer sequences (columns “Sequence Fw (5’-3’)” and “Sequence
1480 Fw (5’-3’)”), lowercase letters are the T7 promoter sequence used for in vitro transcription. The
1481 respective primer Tm values and the product lengths are provided in columns “Fw Tm (°C)”,
1482 “Rv Tm (°C)”, and “Product size (bp)”.

1483 **Supplementary Table 2.** Observed and expected values of mortality in the backcross ((LON
1484 ♀ × HPC ♂)♀ x LON ♂) made to determine the chlorfenapyr mode of inheritance, together
1485 with the corresponding X^2 for the monogenic inheritance hypothesis. Expected mortality
1486 calculated via formula of Georgiou $c = (0.5) W_{LON \times HPC} + (0.5) W_{LON}$, where c is the expected
1487 mortality at each given concentration and W is the observed mortality of the F₁ LON x HPC
1488 and parental LON genotypes at each given concentration. LC₅₀s of SR and RS populations
1489 together with the dominance values (D values).

1490 **Supplementary Table 3.** Number of generated strand-specific paired-end Illumina reads and
1491 their mapping rates against the *Tetranychus urticae* 3 chromosome assembly for all sample
1492 groups.

1493 **Supplementary Table 4.** Gene ID’s of all genes that show significant differences in expression
1494 across all samples based on z-scaled normalized read-counts (p value < 0.001 as determined by
1495 LTR test), grouped into 13 clusters with the k-means clustering algorithm.

1496 **Supplementary Table 5.** Enriched GO terms per cluster.

1497 **Supplementary Table 6.** Differentially expressed genes (DEGs, absolute Log₂ Fold Change
1498 ($|\text{Log}_2\text{FC}| > 1, p \text{ adj} < 0.05$) in all pairwise comparisons between LON, JW, HP, HPA, HPAexp,
1499 HPC and HPCexp. For each comparison, Log₂ fold change (Log₂FC), standard error for Log₂FC,
1500 and adjusted p values for each gene are provided in columns “Log₂FC”, “lfcSE”, and “ p adj”,
1501 respectively.

1502 **Supplementary Table 7.** Numbers of differentially expressed genes in different comparisons
1503 between LON, JW, HP, HPA, HPAexp, HPC and HPCexp. Upregulated genes are DEGs with
1504 Log₂FC > 1, downregulated genes are DEGs with Log₂FC < -1.

1505 **Supplementary Table 8.** Cytochrome P450 genes per cluster.

1506 **Supplementary Table 9.** Yields of *T. urticae* P450s expressed in *E. coli* with their
1507 characteristic CO-reduced spectrum.

1508 **Supplementary Table 10.** Genes located at genomic window of each QTL. For QTL1 (~20.850
1509 Mb on chromosome 1) genes from 100 kb downstream of the amitraz BSA average (~20.558
1510 Mb; indicated in blue shading) to 100 kb upstream of the chlorfenapyr BSA average (~21.108
1511 Mb; indicated in red shading). For QTL2 and QTL3 genes in a 100 kb bracket of the amitraz
1512 BSA average (~3.008 Mb and ~17.263 Mb on chromosome 3, respectively; indicated in blue
1513 shading). Log₂FC of DEGs between parental strains HPC and ROS-ITi are shown, with n.s.
1514 meaning not significant ($p \text{ adj} > 0.05$). For QTL 1 AA mutations enriched in selected samples
1515 are shown for both BSA experiments.

1516 **Supplementary Table 11.** : Output of DESeq2 for pairwise comparisons to identify
1517 differentially expressed genes between mites injected with dsHR96 (treatment) versus dsGFP
1518 (control). Here, all genes with p value < 0.05 are presented. For each comparison, Log₂ fold
1519 change (Log₂FC), standard error for Log₂FC, and adjusted p values for each gene are provided
1520 in columns “log2FC”, “lfcSE”, and “ p adj”, respectively.

1521

1522

